{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 98,
   "metadata": {},
   "outputs": [],
   "source": [
    "import sys\n",
    "sys.path.append('~/ner')\n",
    "import config\n",
    "from tqdm.notebook import tqdm\n",
    "import csv"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 99,
   "metadata": {},
   "outputs": [],
   "source": [
    "cursor = config.coll.aggregate([{\n",
    "    '$match': {\n",
    "        '$and': [{\n",
    "            'primary_outcomes': {'$not': {'$size': 0}}},{\n",
    "            'secondary_outcomes': {'$not': {'$size': 0}}}\n",
    "]}}, \n",
    "    {\n",
    "        '$sample': {'size': 1000}},\n",
    "    {\n",
    "        '$project':{'primary_outcomes':1, 'secondary_outcomes':1, 'conditions': 1}}])\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 100,
   "metadata": {},
   "outputs": [],
   "source": [
    "class Rule_based_annotation():\n",
    "    def __init__(self, cursor):\n",
    "        self.cursor = cursor\n",
    "    \n",
    "    def expand_outcomes(self, measure, item):\n",
    "        self.tag_corpus['NCT'].append('%s; %s'%(item['_id'], ', '.join(item['conditions'])))\n",
    "        self.tag_corpus['measure'].append(measure['measure'])\n",
    "        \n",
    "        get_val = lambda x: measure[x] if measure.get(x)!=None else ''\n",
    "        \n",
    "        self.tag_corpus['safety_issue'].append(get_val('safety_issue'))\n",
    "        self.tag_corpus['description'].append(get_val('description'))\n",
    "    \n",
    "    def parse_cursor(self):\n",
    "        self.tag_corpus = {'NCT': [],'measure': [], 'safety_issue': [], 'description': [], 'time_frame': []}\n",
    "        for item in self.cursor:\n",
    "            for measure in item['primary_outcomes']: \n",
    "                 self.expand_outcomes(measure, item)\n",
    "            for measure in item['secondary_outcomes']:\n",
    "                 self.expand_outcomes(measure, item)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 101,
   "metadata": {},
   "outputs": [],
   "source": [
    "cls = Rule_based_annotation(cursor)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 102,
   "metadata": {},
   "outputs": [],
   "source": [
    "cls.parse_cursor()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 116,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['NCT02551094; Coronary Artery Disease, Myocardial Infarction',\n",
       " 'NCT02551094; Coronary Artery Disease, Myocardial Infarction',\n",
       " 'NCT02551094; Coronary Artery Disease, Myocardial Infarction',\n",
       " 'NCT02551094; Coronary Artery Disease, Myocardial Infarction',\n",
       " 'NCT02551094; Coronary Artery Disease, Myocardial Infarction',\n",
       " 'NCT02551094; Coronary Artery Disease, Myocardial Infarction',\n",
       " 'NCT02551094; Coronary Artery Disease, Myocardial Infarction',\n",
       " 'NCT02551094; Coronary Artery Disease, Myocardial Infarction',\n",
       " 'NCT01840904; Acute Diverticulitis',\n",
       " 'NCT01840904; Acute Diverticulitis',\n",
       " 'NCT01840904; Acute Diverticulitis',\n",
       " 'NCT01840904; Acute Diverticulitis',\n",
       " 'NCT01840904; Acute Diverticulitis',\n",
       " 'NCT01840904; Acute Diverticulitis',\n",
       " 'NCT01840904; Acute Diverticulitis',\n",
       " 'NCT01840904; Acute Diverticulitis',\n",
       " 'NCT01840904; Acute Diverticulitis',\n",
       " 'NCT01840904; Acute Diverticulitis',\n",
       " 'NCT01840904; Acute Diverticulitis',\n",
       " 'NCT02137941; Stress, Anxiety',\n",
       " 'NCT02137941; Stress, Anxiety',\n",
       " 'NCT02137941; Stress, Anxiety',\n",
       " 'NCT02137941; Stress, Anxiety',\n",
       " 'NCT02137941; Stress, Anxiety',\n",
       " 'NCT02137941; Stress, Anxiety',\n",
       " 'NCT02137941; Stress, Anxiety',\n",
       " 'NCT02137941; Stress, Anxiety',\n",
       " 'NCT02788461; Non-Small Cell Lung Cancer',\n",
       " 'NCT02788461; Non-Small Cell Lung Cancer',\n",
       " 'NCT02788461; Non-Small Cell Lung Cancer',\n",
       " 'NCT02788461; Non-Small Cell Lung Cancer',\n",
       " 'NCT02788461; Non-Small Cell Lung Cancer',\n",
       " 'NCT02788461; Non-Small Cell Lung Cancer',\n",
       " 'NCT02788461; Non-Small Cell Lung Cancer',\n",
       " 'NCT02788461; Non-Small Cell Lung Cancer',\n",
       " 'NCT02788461; Non-Small Cell Lung Cancer',\n",
       " \"NCT01569503; Crohn's Disease\",\n",
       " \"NCT01569503; Crohn's Disease\",\n",
       " \"NCT01569503; Crohn's Disease\",\n",
       " \"NCT01569503; Crohn's Disease\",\n",
       " \"NCT01569503; Crohn's Disease\",\n",
       " \"NCT01569503; Crohn's Disease\",\n",
       " \"NCT01569503; Crohn's Disease\",\n",
       " 'NCT00981617; Alcohol Dependence',\n",
       " 'NCT00981617; Alcohol Dependence',\n",
       " 'NCT00981617; Alcohol Dependence',\n",
       " 'NCT00981617; Alcohol Dependence',\n",
       " 'NCT00981617; Alcohol Dependence',\n",
       " 'NCT00981617; Alcohol Dependence',\n",
       " 'NCT00981617; Alcohol Dependence',\n",
       " 'NCT00106301; Carcinoma, Renal Cell, Prostatic Neoplasms',\n",
       " 'NCT00106301; Carcinoma, Renal Cell, Prostatic Neoplasms',\n",
       " 'NCT00106301; Carcinoma, Renal Cell, Prostatic Neoplasms',\n",
       " 'NCT00629863; Esophageal Cancer, Gastric Cancer',\n",
       " 'NCT00629863; Esophageal Cancer, Gastric Cancer',\n",
       " 'NCT00629863; Esophageal Cancer, Gastric Cancer',\n",
       " 'NCT00629863; Esophageal Cancer, Gastric Cancer',\n",
       " 'NCT01585051; Diabetes Mellitus Type 2',\n",
       " 'NCT01585051; Diabetes Mellitus Type 2',\n",
       " 'NCT01585051; Diabetes Mellitus Type 2',\n",
       " 'NCT01585051; Diabetes Mellitus Type 2',\n",
       " 'NCT02090985; Stoma',\n",
       " 'NCT02090985; Stoma',\n",
       " 'NCT02090985; Stoma',\n",
       " 'NCT02090985; Stoma',\n",
       " 'NCT02600611; Skin Structures and Soft Tissue Infections',\n",
       " 'NCT02600611; Skin Structures and Soft Tissue Infections',\n",
       " 'NCT00702169; Mechanical Ventilation',\n",
       " 'NCT00702169; Mechanical Ventilation',\n",
       " 'NCT02673801; Osteoarthritis, Knee',\n",
       " 'NCT02673801; Osteoarthritis, Knee',\n",
       " 'NCT03399227; Liver Diseases, Transplant-Related Disorder, Osteoporosis',\n",
       " 'NCT03399227; Liver Diseases, Transplant-Related Disorder, Osteoporosis',\n",
       " 'NCT03399227; Liver Diseases, Transplant-Related Disorder, Osteoporosis',\n",
       " 'NCT03399227; Liver Diseases, Transplant-Related Disorder, Osteoporosis',\n",
       " 'NCT03399227; Liver Diseases, Transplant-Related Disorder, Osteoporosis',\n",
       " 'NCT03399227; Liver Diseases, Transplant-Related Disorder, Osteoporosis',\n",
       " 'NCT01509079; Muscle Pain, Joint Pain',\n",
       " 'NCT01509079; Muscle Pain, Joint Pain',\n",
       " 'NCT01509079; Muscle Pain, Joint Pain',\n",
       " 'NCT01509079; Muscle Pain, Joint Pain',\n",
       " 'NCT01509079; Muscle Pain, Joint Pain',\n",
       " 'NCT01509079; Muscle Pain, Joint Pain',\n",
       " 'NCT01509079; Muscle Pain, Joint Pain',\n",
       " 'NCT01509079; Muscle Pain, Joint Pain',\n",
       " 'NCT01099904; Healthy Volunteer',\n",
       " 'NCT01099904; Healthy Volunteer',\n",
       " 'NCT03386110; Risk Behavior, Drug Use, Sex, Anal',\n",
       " 'NCT03386110; Risk Behavior, Drug Use, Sex, Anal',\n",
       " 'NCT03386110; Risk Behavior, Drug Use, Sex, Anal',\n",
       " 'NCT03386110; Risk Behavior, Drug Use, Sex, Anal',\n",
       " 'NCT03386110; Risk Behavior, Drug Use, Sex, Anal',\n",
       " 'NCT02393274; Heart Failure, Respiratory Failure',\n",
       " 'NCT02393274; Heart Failure, Respiratory Failure',\n",
       " 'NCT02393274; Heart Failure, Respiratory Failure',\n",
       " 'NCT02393274; Heart Failure, Respiratory Failure',\n",
       " 'NCT02380768; Supraglottic Airway',\n",
       " 'NCT02380768; Supraglottic Airway',\n",
       " 'NCT02380768; Supraglottic Airway',\n",
       " 'NCT02380768; Supraglottic Airway',\n",
       " 'NCT02380768; Supraglottic Airway',\n",
       " 'NCT02380768; Supraglottic Airway',\n",
       " 'NCT02380768; Supraglottic Airway',\n",
       " 'NCT02380768; Supraglottic Airway',\n",
       " 'NCT02380768; Supraglottic Airway',\n",
       " 'NCT02380768; Supraglottic Airway',\n",
       " 'NCT00185939; Bite, Wound, Infection',\n",
       " 'NCT00185939; Bite, Wound, Infection',\n",
       " 'NCT02309944; Postoperative Complications, Obesity, Gynecologic Neoplasms',\n",
       " 'NCT02309944; Postoperative Complications, Obesity, Gynecologic Neoplasms',\n",
       " 'NCT01601678; Achalasia',\n",
       " 'NCT01601678; Achalasia',\n",
       " 'NCT01601678; Achalasia',\n",
       " 'NCT01601678; Achalasia',\n",
       " 'NCT01601678; Achalasia',\n",
       " 'NCT01601678; Achalasia',\n",
       " 'NCT01601678; Achalasia',\n",
       " 'NCT01601678; Achalasia',\n",
       " 'NCT01601678; Achalasia',\n",
       " 'NCT01601678; Achalasia',\n",
       " 'NCT01601678; Achalasia',\n",
       " 'NCT01601678; Achalasia',\n",
       " 'NCT01601678; Achalasia',\n",
       " 'NCT01601678; Achalasia',\n",
       " 'NCT01601678; Achalasia',\n",
       " 'NCT01601678; Achalasia',\n",
       " 'NCT01601678; Achalasia',\n",
       " 'NCT01601678; Achalasia',\n",
       " 'NCT03428178; Acute LHON, Onset Within Three Months, Onset Between 3 to 6 Months, Onset Between 6 to 12 Months, Onset Between 12 to 24 Months, Onset Between 24 to 60 Months, Onset Over 60 Months',\n",
       " 'NCT03428178; Acute LHON, Onset Within Three Months, Onset Between 3 to 6 Months, Onset Between 6 to 12 Months, Onset Between 12 to 24 Months, Onset Between 24 to 60 Months, Onset Over 60 Months',\n",
       " 'NCT03428178; Acute LHON, Onset Within Three Months, Onset Between 3 to 6 Months, Onset Between 6 to 12 Months, Onset Between 12 to 24 Months, Onset Between 24 to 60 Months, Onset Over 60 Months',\n",
       " 'NCT03428178; Acute LHON, Onset Within Three Months, Onset Between 3 to 6 Months, Onset Between 6 to 12 Months, Onset Between 12 to 24 Months, Onset Between 24 to 60 Months, Onset Over 60 Months',\n",
       " 'NCT03428178; Acute LHON, Onset Within Three Months, Onset Between 3 to 6 Months, Onset Between 6 to 12 Months, Onset Between 12 to 24 Months, Onset Between 24 to 60 Months, Onset Over 60 Months',\n",
       " 'NCT03428178; Acute LHON, Onset Within Three Months, Onset Between 3 to 6 Months, Onset Between 6 to 12 Months, Onset Between 12 to 24 Months, Onset Between 24 to 60 Months, Onset Over 60 Months',\n",
       " 'NCT03428178; Acute LHON, Onset Within Three Months, Onset Between 3 to 6 Months, Onset Between 6 to 12 Months, Onset Between 12 to 24 Months, Onset Between 24 to 60 Months, Onset Over 60 Months',\n",
       " 'NCT00552292; Metabolic Syndrome, Hypertension, Obesity, Dyslipidemia, Hyperglycemia',\n",
       " 'NCT00552292; Metabolic Syndrome, Hypertension, Obesity, Dyslipidemia, Hyperglycemia',\n",
       " 'NCT01710592; Gastro Oesophageal Cancer',\n",
       " 'NCT01710592; Gastro Oesophageal Cancer',\n",
       " 'NCT01710592; Gastro Oesophageal Cancer',\n",
       " 'NCT01710592; Gastro Oesophageal Cancer',\n",
       " 'NCT01710592; Gastro Oesophageal Cancer',\n",
       " 'NCT00996801; Osteoporosis, Postmenopausal Osteoporosis',\n",
       " 'NCT00996801; Osteoporosis, Postmenopausal Osteoporosis',\n",
       " 'NCT00996801; Osteoporosis, Postmenopausal Osteoporosis',\n",
       " 'NCT00996801; Osteoporosis, Postmenopausal Osteoporosis',\n",
       " 'NCT00996801; Osteoporosis, Postmenopausal Osteoporosis',\n",
       " 'NCT00996801; Osteoporosis, Postmenopausal Osteoporosis',\n",
       " 'NCT00996801; Osteoporosis, Postmenopausal Osteoporosis',\n",
       " 'NCT00996801; Osteoporosis, Postmenopausal Osteoporosis',\n",
       " 'NCT00996801; Osteoporosis, Postmenopausal Osteoporosis',\n",
       " 'NCT00996801; Osteoporosis, Postmenopausal Osteoporosis',\n",
       " 'NCT00996801; Osteoporosis, Postmenopausal Osteoporosis',\n",
       " 'NCT00996801; Osteoporosis, Postmenopausal Osteoporosis',\n",
       " 'NCT00996801; Osteoporosis, Postmenopausal Osteoporosis',\n",
       " 'NCT00996801; Osteoporosis, Postmenopausal Osteoporosis',\n",
       " 'NCT00996801; Osteoporosis, Postmenopausal Osteoporosis',\n",
       " 'NCT00996801; Osteoporosis, Postmenopausal Osteoporosis',\n",
       " 'NCT00996801; Osteoporosis, Postmenopausal Osteoporosis',\n",
       " 'NCT00996801; Osteoporosis, Postmenopausal Osteoporosis',\n",
       " 'NCT00854529; Bleb Vascularity, Bleb Fibrosis, Trabeculectomy Failure',\n",
       " 'NCT00854529; Bleb Vascularity, Bleb Fibrosis, Trabeculectomy Failure',\n",
       " 'NCT00854529; Bleb Vascularity, Bleb Fibrosis, Trabeculectomy Failure',\n",
       " 'NCT00854529; Bleb Vascularity, Bleb Fibrosis, Trabeculectomy Failure',\n",
       " 'NCT03627000; Bone and Joint Infection, Bacterial Infections, EPIDEMIOLOGY',\n",
       " 'NCT03627000; Bone and Joint Infection, Bacterial Infections, EPIDEMIOLOGY',\n",
       " 'NCT03627000; Bone and Joint Infection, Bacterial Infections, EPIDEMIOLOGY',\n",
       " 'NCT01967095; EGFR-Mutant Lung Cancer',\n",
       " 'NCT01967095; EGFR-Mutant Lung Cancer',\n",
       " 'NCT01967095; EGFR-Mutant Lung Cancer',\n",
       " 'NCT01967095; EGFR-Mutant Lung Cancer',\n",
       " 'NCT01967095; EGFR-Mutant Lung Cancer',\n",
       " 'NCT04071743; Post-Traumatic Headache',\n",
       " 'NCT04071743; Post-Traumatic Headache',\n",
       " 'NCT00908700; Atrial Fibrillation, Stroke',\n",
       " 'NCT00908700; Atrial Fibrillation, Stroke',\n",
       " 'NCT04155034; Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma, Lung Small Cell Carcinoma',\n",
       " 'NCT04155034; Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma, Lung Small Cell Carcinoma',\n",
       " 'NCT04155034; Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma, Lung Small Cell Carcinoma',\n",
       " 'NCT04155034; Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma, Lung Small Cell Carcinoma',\n",
       " 'NCT04155034; Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma, Lung Small Cell Carcinoma',\n",
       " 'NCT04155034; Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma, Lung Small Cell Carcinoma',\n",
       " 'NCT04155034; Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma, Lung Small Cell Carcinoma',\n",
       " 'NCT00879073; Brain Metastases',\n",
       " 'NCT00879073; Brain Metastases',\n",
       " 'NCT02175940; Myopic Choroidal Neovascularization, VEGF Aqueous Level, PEDF Aqueous Level',\n",
       " 'NCT02175940; Myopic Choroidal Neovascularization, VEGF Aqueous Level, PEDF Aqueous Level',\n",
       " 'NCT02175940; Myopic Choroidal Neovascularization, VEGF Aqueous Level, PEDF Aqueous Level',\n",
       " 'NCT02175940; Myopic Choroidal Neovascularization, VEGF Aqueous Level, PEDF Aqueous Level',\n",
       " 'NCT01366196; Lumbar Spinal Fusions',\n",
       " 'NCT01366196; Lumbar Spinal Fusions',\n",
       " 'NCT02425995; Chronic Knee Instability',\n",
       " 'NCT02425995; Chronic Knee Instability',\n",
       " 'NCT02611518; Healthy',\n",
       " 'NCT02611518; Healthy',\n",
       " 'NCT02611518; Healthy',\n",
       " 'NCT02611518; Healthy',\n",
       " 'NCT03036371; Anxiety',\n",
       " 'NCT03036371; Anxiety',\n",
       " 'NCT03036371; Anxiety',\n",
       " 'NCT03036371; Anxiety',\n",
       " 'NCT03036371; Anxiety',\n",
       " 'NCT01729286; Foot Ulcer, Diabetic',\n",
       " 'NCT01729286; Foot Ulcer, Diabetic',\n",
       " 'NCT01729286; Foot Ulcer, Diabetic',\n",
       " 'NCT01729286; Foot Ulcer, Diabetic',\n",
       " 'NCT03815656; Parkinson Disease',\n",
       " 'NCT03815656; Parkinson Disease',\n",
       " 'NCT03815656; Parkinson Disease',\n",
       " 'NCT03815656; Parkinson Disease',\n",
       " 'NCT03815656; Parkinson Disease',\n",
       " 'NCT00279409; Attention Deficit Hyperactivity Disorder',\n",
       " 'NCT00279409; Attention Deficit Hyperactivity Disorder',\n",
       " 'NCT00279409; Attention Deficit Hyperactivity Disorder',\n",
       " 'NCT00279409; Attention Deficit Hyperactivity Disorder',\n",
       " 'NCT00279409; Attention Deficit Hyperactivity Disorder',\n",
       " 'NCT00279409; Attention Deficit Hyperactivity Disorder',\n",
       " 'NCT01809964; Lateral Canthal Lines, Crows Feet',\n",
       " 'NCT01809964; Lateral Canthal Lines, Crows Feet',\n",
       " 'NCT00175734; Diabetes',\n",
       " 'NCT00175734; Diabetes',\n",
       " 'NCT01815814; Spastic Cerebral Palsy',\n",
       " 'NCT01815814; Spastic Cerebral Palsy',\n",
       " 'NCT02269410; Obesity',\n",
       " 'NCT02269410; Obesity',\n",
       " 'NCT02269410; Obesity',\n",
       " 'NCT02269410; Obesity',\n",
       " 'NCT02269410; Obesity',\n",
       " 'NCT02269410; Obesity',\n",
       " 'NCT00354666; Pulmonary Disease, Chronic Obstructive',\n",
       " 'NCT00354666; Pulmonary Disease, Chronic Obstructive',\n",
       " 'NCT02328846; Bypass Complications',\n",
       " 'NCT02328846; Bypass Complications',\n",
       " 'NCT04155619; Diabetes Mellitus, Type 2, Time Restricted Feeding, Light; Therapy, Complications',\n",
       " 'NCT04155619; Diabetes Mellitus, Type 2, Time Restricted Feeding, Light; Therapy, Complications',\n",
       " 'NCT04155619; Diabetes Mellitus, Type 2, Time Restricted Feeding, Light; Therapy, Complications',\n",
       " 'NCT04155619; Diabetes Mellitus, Type 2, Time Restricted Feeding, Light; Therapy, Complications',\n",
       " 'NCT04155619; Diabetes Mellitus, Type 2, Time Restricted Feeding, Light; Therapy, Complications',\n",
       " 'NCT04155619; Diabetes Mellitus, Type 2, Time Restricted Feeding, Light; Therapy, Complications',\n",
       " 'NCT04155619; Diabetes Mellitus, Type 2, Time Restricted Feeding, Light; Therapy, Complications',\n",
       " 'NCT04155619; Diabetes Mellitus, Type 2, Time Restricted Feeding, Light; Therapy, Complications',\n",
       " 'NCT04155619; Diabetes Mellitus, Type 2, Time Restricted Feeding, Light; Therapy, Complications',\n",
       " 'NCT04155619; Diabetes Mellitus, Type 2, Time Restricted Feeding, Light; Therapy, Complications',\n",
       " 'NCT04155619; Diabetes Mellitus, Type 2, Time Restricted Feeding, Light; Therapy, Complications',\n",
       " 'NCT04155619; Diabetes Mellitus, Type 2, Time Restricted Feeding, Light; Therapy, Complications',\n",
       " 'NCT04155619; Diabetes Mellitus, Type 2, Time Restricted Feeding, Light; Therapy, Complications',\n",
       " 'NCT04241835; Hepatic Impairment, Advanced Malignant Solid Tumor',\n",
       " 'NCT04241835; Hepatic Impairment, Advanced Malignant Solid Tumor',\n",
       " 'NCT04241835; Hepatic Impairment, Advanced Malignant Solid Tumor',\n",
       " 'NCT04241835; Hepatic Impairment, Advanced Malignant Solid Tumor',\n",
       " 'NCT04241835; Hepatic Impairment, Advanced Malignant Solid Tumor',\n",
       " 'NCT04241835; Hepatic Impairment, Advanced Malignant Solid Tumor',\n",
       " 'NCT04241835; Hepatic Impairment, Advanced Malignant Solid Tumor',\n",
       " 'NCT04241835; Hepatic Impairment, Advanced Malignant Solid Tumor',\n",
       " 'NCT04241835; Hepatic Impairment, Advanced Malignant Solid Tumor',\n",
       " 'NCT04241835; Hepatic Impairment, Advanced Malignant Solid Tumor',\n",
       " 'NCT04241835; Hepatic Impairment, Advanced Malignant Solid Tumor',\n",
       " 'NCT04241835; Hepatic Impairment, Advanced Malignant Solid Tumor',\n",
       " 'NCT04241835; Hepatic Impairment, Advanced Malignant Solid Tumor',\n",
       " 'NCT04241835; Hepatic Impairment, Advanced Malignant Solid Tumor',\n",
       " 'NCT04241835; Hepatic Impairment, Advanced Malignant Solid Tumor',\n",
       " 'NCT04241835; Hepatic Impairment, Advanced Malignant Solid Tumor',\n",
       " 'NCT04241835; Hepatic Impairment, Advanced Malignant Solid Tumor',\n",
       " 'NCT04241835; Hepatic Impairment, Advanced Malignant Solid Tumor',\n",
       " 'NCT04241835; Hepatic Impairment, Advanced Malignant Solid Tumor',\n",
       " 'NCT04241835; Hepatic Impairment, Advanced Malignant Solid Tumor',\n",
       " 'NCT02877979; HIV',\n",
       " 'NCT02877979; HIV',\n",
       " 'NCT00424463; Amyotrophic Lateral Sclerosis (ALS)',\n",
       " 'NCT00424463; Amyotrophic Lateral Sclerosis (ALS)',\n",
       " 'NCT00424463; Amyotrophic Lateral Sclerosis (ALS)',\n",
       " 'NCT00424463; Amyotrophic Lateral Sclerosis (ALS)',\n",
       " 'NCT00424463; Amyotrophic Lateral Sclerosis (ALS)',\n",
       " 'NCT00424463; Amyotrophic Lateral Sclerosis (ALS)',\n",
       " 'NCT00424463; Amyotrophic Lateral Sclerosis (ALS)',\n",
       " 'NCT01487161; Osteoarthritis of the Knee',\n",
       " 'NCT01487161; Osteoarthritis of the Knee',\n",
       " 'NCT01487161; Osteoarthritis of the Knee',\n",
       " 'NCT01487161; Osteoarthritis of the Knee',\n",
       " 'NCT01487161; Osteoarthritis of the Knee',\n",
       " 'NCT01487161; Osteoarthritis of the Knee',\n",
       " 'NCT01487161; Osteoarthritis of the Knee',\n",
       " 'NCT01487161; Osteoarthritis of the Knee',\n",
       " 'NCT01487161; Osteoarthritis of the Knee',\n",
       " 'NCT01487161; Osteoarthritis of the Knee',\n",
       " 'NCT01487161; Osteoarthritis of the Knee',\n",
       " 'NCT01487161; Osteoarthritis of the Knee',\n",
       " 'NCT01487161; Osteoarthritis of the Knee',\n",
       " 'NCT01487161; Osteoarthritis of the Knee',\n",
       " 'NCT01487161; Osteoarthritis of the Knee',\n",
       " 'NCT01487161; Osteoarthritis of the Knee',\n",
       " 'NCT03465839; General Surgery',\n",
       " 'NCT03465839; General Surgery',\n",
       " 'NCT03465839; General Surgery',\n",
       " 'NCT03465839; General Surgery',\n",
       " 'NCT00866034; In Vitro Fertilization, Intracytoplasmic Sperm Injection',\n",
       " 'NCT00866034; In Vitro Fertilization, Intracytoplasmic Sperm Injection',\n",
       " 'NCT04055259; Overweight and Obesity, Health Behavior',\n",
       " 'NCT04055259; Overweight and Obesity, Health Behavior',\n",
       " 'NCT04055259; Overweight and Obesity, Health Behavior',\n",
       " 'NCT04055259; Overweight and Obesity, Health Behavior',\n",
       " 'NCT04055259; Overweight and Obesity, Health Behavior',\n",
       " 'NCT00397033; Schizoaffective Disorder, Psychotic Disorder',\n",
       " 'NCT00397033; Schizoaffective Disorder, Psychotic Disorder',\n",
       " 'NCT00397033; Schizoaffective Disorder, Psychotic Disorder',\n",
       " 'NCT00397033; Schizoaffective Disorder, Psychotic Disorder',\n",
       " 'NCT00397033; Schizoaffective Disorder, Psychotic Disorder',\n",
       " 'NCT00397033; Schizoaffective Disorder, Psychotic Disorder',\n",
       " 'NCT00397033; Schizoaffective Disorder, Psychotic Disorder',\n",
       " 'NCT00397033; Schizoaffective Disorder, Psychotic Disorder',\n",
       " 'NCT00397033; Schizoaffective Disorder, Psychotic Disorder',\n",
       " 'NCT00397033; Schizoaffective Disorder, Psychotic Disorder',\n",
       " 'NCT00397033; Schizoaffective Disorder, Psychotic Disorder',\n",
       " 'NCT00397033; Schizoaffective Disorder, Psychotic Disorder',\n",
       " 'NCT00397033; Schizoaffective Disorder, Psychotic Disorder',\n",
       " 'NCT00397033; Schizoaffective Disorder, Psychotic Disorder',\n",
       " 'NCT01639911; Malignant Neoplasm of Breast, CNS Malignancy, Malignant Neoplasm of Gastrointestinal Tract, Genitourinary Neoplasms Malignancy and Gender Unspecified, Head and Neck Neoplasms, Melanoma, Malignant Neoplasm of Thorax',\n",
       " 'NCT01639911; Malignant Neoplasm of Breast, CNS Malignancy, Malignant Neoplasm of Gastrointestinal Tract, Genitourinary Neoplasms Malignancy and Gender Unspecified, Head and Neck Neoplasms, Melanoma, Malignant Neoplasm of Thorax',\n",
       " 'NCT01149590; Angina Pectoris, Coronary Heart Disease',\n",
       " 'NCT01149590; Angina Pectoris, Coronary Heart Disease',\n",
       " 'NCT01149590; Angina Pectoris, Coronary Heart Disease',\n",
       " 'NCT01149590; Angina Pectoris, Coronary Heart Disease',\n",
       " 'NCT01149590; Angina Pectoris, Coronary Heart Disease',\n",
       " 'NCT01149590; Angina Pectoris, Coronary Heart Disease',\n",
       " 'NCT01717287; HIV Infection',\n",
       " 'NCT01717287; HIV Infection',\n",
       " 'NCT01717287; HIV Infection',\n",
       " 'NCT01717287; HIV Infection',\n",
       " 'NCT01717287; HIV Infection',\n",
       " 'NCT01717287; HIV Infection',\n",
       " 'NCT01717287; HIV Infection',\n",
       " 'NCT01717287; HIV Infection',\n",
       " 'NCT01717287; HIV Infection',\n",
       " \"NCT01833884; Hodgkin's Disease\",\n",
       " \"NCT01833884; Hodgkin's Disease\",\n",
       " 'NCT03060096; Anxiety, Depressive Symptoms, Sleep Disturbance, Recurrent Disease, Fatigue, Quality of Life, Cancer',\n",
       " 'NCT03060096; Anxiety, Depressive Symptoms, Sleep Disturbance, Recurrent Disease, Fatigue, Quality of Life, Cancer',\n",
       " 'NCT03060096; Anxiety, Depressive Symptoms, Sleep Disturbance, Recurrent Disease, Fatigue, Quality of Life, Cancer',\n",
       " 'NCT03060096; Anxiety, Depressive Symptoms, Sleep Disturbance, Recurrent Disease, Fatigue, Quality of Life, Cancer',\n",
       " 'NCT03060096; Anxiety, Depressive Symptoms, Sleep Disturbance, Recurrent Disease, Fatigue, Quality of Life, Cancer',\n",
       " 'NCT03060096; Anxiety, Depressive Symptoms, Sleep Disturbance, Recurrent Disease, Fatigue, Quality of Life, Cancer',\n",
       " 'NCT03060096; Anxiety, Depressive Symptoms, Sleep Disturbance, Recurrent Disease, Fatigue, Quality of Life, Cancer',\n",
       " 'NCT03060096; Anxiety, Depressive Symptoms, Sleep Disturbance, Recurrent Disease, Fatigue, Quality of Life, Cancer',\n",
       " 'NCT03060096; Anxiety, Depressive Symptoms, Sleep Disturbance, Recurrent Disease, Fatigue, Quality of Life, Cancer',\n",
       " 'NCT03060096; Anxiety, Depressive Symptoms, Sleep Disturbance, Recurrent Disease, Fatigue, Quality of Life, Cancer',\n",
       " 'NCT03060096; Anxiety, Depressive Symptoms, Sleep Disturbance, Recurrent Disease, Fatigue, Quality of Life, Cancer',\n",
       " 'NCT03060096; Anxiety, Depressive Symptoms, Sleep Disturbance, Recurrent Disease, Fatigue, Quality of Life, Cancer',\n",
       " 'NCT03060096; Anxiety, Depressive Symptoms, Sleep Disturbance, Recurrent Disease, Fatigue, Quality of Life, Cancer',\n",
       " 'NCT03060096; Anxiety, Depressive Symptoms, Sleep Disturbance, Recurrent Disease, Fatigue, Quality of Life, Cancer',\n",
       " 'NCT00306059; Kidney Injury, Acute',\n",
       " 'NCT00306059; Kidney Injury, Acute',\n",
       " 'NCT00306059; Kidney Injury, Acute',\n",
       " 'NCT00306059; Kidney Injury, Acute',\n",
       " 'NCT01018056; Tourette Syndrome',\n",
       " 'NCT01018056; Tourette Syndrome',\n",
       " 'NCT01018056; Tourette Syndrome',\n",
       " 'NCT01018056; Tourette Syndrome',\n",
       " 'NCT01018056; Tourette Syndrome',\n",
       " 'NCT01018056; Tourette Syndrome',\n",
       " 'NCT01018056; Tourette Syndrome',\n",
       " 'NCT01018056; Tourette Syndrome',\n",
       " 'NCT01018056; Tourette Syndrome',\n",
       " 'NCT01018056; Tourette Syndrome',\n",
       " 'NCT01018056; Tourette Syndrome',\n",
       " 'NCT01018056; Tourette Syndrome',\n",
       " 'NCT01018056; Tourette Syndrome',\n",
       " 'NCT01018056; Tourette Syndrome',\n",
       " 'NCT04110977; Radiation Dermatitis, Radiation-induced Oral Mucositis',\n",
       " 'NCT04110977; Radiation Dermatitis, Radiation-induced Oral Mucositis',\n",
       " 'NCT04110977; Radiation Dermatitis, Radiation-induced Oral Mucositis',\n",
       " 'NCT04110977; Radiation Dermatitis, Radiation-induced Oral Mucositis',\n",
       " 'NCT04110977; Radiation Dermatitis, Radiation-induced Oral Mucositis',\n",
       " 'NCT04110977; Radiation Dermatitis, Radiation-induced Oral Mucositis',\n",
       " 'NCT00860054; Hypercholesterolemia, Coronary Heart Disease',\n",
       " 'NCT00860054; Hypercholesterolemia, Coronary Heart Disease',\n",
       " 'NCT03432819; HIV',\n",
       " 'NCT03432819; HIV',\n",
       " 'NCT03432819; HIV',\n",
       " 'NCT03432819; HIV',\n",
       " 'NCT02365324; Obesity, Physical Activity',\n",
       " 'NCT02365324; Obesity, Physical Activity',\n",
       " 'NCT02365324; Obesity, Physical Activity',\n",
       " 'NCT02365324; Obesity, Physical Activity',\n",
       " 'NCT02365324; Obesity, Physical Activity',\n",
       " 'NCT02365324; Obesity, Physical Activity',\n",
       " 'NCT02365324; Obesity, Physical Activity',\n",
       " 'NCT02365324; Obesity, Physical Activity',\n",
       " 'NCT02365324; Obesity, Physical Activity',\n",
       " 'NCT02365324; Obesity, Physical Activity',\n",
       " 'NCT02365324; Obesity, Physical Activity',\n",
       " 'NCT02365324; Obesity, Physical Activity',\n",
       " 'NCT00440128; Nausea and Vomiting, Chemotherapy-Induced',\n",
       " 'NCT00440128; Nausea and Vomiting, Chemotherapy-Induced',\n",
       " 'NCT00440128; Nausea and Vomiting, Chemotherapy-Induced',\n",
       " 'NCT00440128; Nausea and Vomiting, Chemotherapy-Induced',\n",
       " 'NCT00440128; Nausea and Vomiting, Chemotherapy-Induced',\n",
       " 'NCT00440128; Nausea and Vomiting, Chemotherapy-Induced',\n",
       " 'NCT00440128; Nausea and Vomiting, Chemotherapy-Induced',\n",
       " 'NCT00440128; Nausea and Vomiting, Chemotherapy-Induced',\n",
       " 'NCT01164605; HIV Infection',\n",
       " 'NCT01164605; HIV Infection',\n",
       " 'NCT01164605; HIV Infection',\n",
       " 'NCT03118102; Hearing Loss',\n",
       " 'NCT03118102; Hearing Loss',\n",
       " 'NCT03541590; Bile Duct Obstruction, Extrahepatic',\n",
       " 'NCT03541590; Bile Duct Obstruction, Extrahepatic',\n",
       " 'NCT03541590; Bile Duct Obstruction, Extrahepatic',\n",
       " 'NCT03541590; Bile Duct Obstruction, Extrahepatic',\n",
       " 'NCT03541590; Bile Duct Obstruction, Extrahepatic',\n",
       " 'NCT00396383; Multiple Myeloma',\n",
       " 'NCT00396383; Multiple Myeloma',\n",
       " 'NCT00396383; Multiple Myeloma',\n",
       " 'NCT00396383; Multiple Myeloma',\n",
       " 'NCT00396383; Multiple Myeloma',\n",
       " 'NCT03090360; Healthy',\n",
       " 'NCT03090360; Healthy',\n",
       " 'NCT03090360; Healthy',\n",
       " 'NCT03090360; Healthy',\n",
       " 'NCT03090360; Healthy',\n",
       " 'NCT03090360; Healthy',\n",
       " 'NCT03090360; Healthy',\n",
       " 'NCT03090360; Healthy',\n",
       " 'NCT00760890; Iron Deficiency',\n",
       " 'NCT00760890; Iron Deficiency',\n",
       " 'NCT00760890; Iron Deficiency',\n",
       " 'NCT04016792; ADHD',\n",
       " 'NCT04016792; ADHD',\n",
       " 'NCT04016792; ADHD',\n",
       " 'NCT04016792; ADHD',\n",
       " 'NCT04016792; ADHD',\n",
       " 'NCT04016792; ADHD',\n",
       " 'NCT04016792; ADHD',\n",
       " 'NCT04016792; ADHD',\n",
       " 'NCT04016792; ADHD',\n",
       " 'NCT04016792; ADHD',\n",
       " 'NCT04016792; ADHD',\n",
       " 'NCT03267641; Hepatocellular Carcinoma',\n",
       " 'NCT03267641; Hepatocellular Carcinoma',\n",
       " 'NCT03267641; Hepatocellular Carcinoma',\n",
       " 'NCT03267641; Hepatocellular Carcinoma',\n",
       " 'NCT02996539; Type2 Diabetes Mellitus',\n",
       " 'NCT02996539; Type2 Diabetes Mellitus',\n",
       " 'NCT00579098; Atrial Fibrillation, Arrhythmia, Inflammation, Endothelial Dysfunction',\n",
       " 'NCT00579098; Atrial Fibrillation, Arrhythmia, Inflammation, Endothelial Dysfunction',\n",
       " 'NCT00579098; Atrial Fibrillation, Arrhythmia, Inflammation, Endothelial Dysfunction',\n",
       " 'NCT00579098; Atrial Fibrillation, Arrhythmia, Inflammation, Endothelial Dysfunction',\n",
       " 'NCT00579098; Atrial Fibrillation, Arrhythmia, Inflammation, Endothelial Dysfunction',\n",
       " 'NCT00820716; Asthma',\n",
       " 'NCT00820716; Asthma',\n",
       " 'NCT00820716; Asthma',\n",
       " 'NCT00820716; Asthma',\n",
       " 'NCT00820716; Asthma',\n",
       " 'NCT02942251; Major Depressive Disorders',\n",
       " 'NCT02942251; Major Depressive Disorders',\n",
       " 'NCT01453439; Body Dysmorphic Disorder, Obsessive-Compulsive Spectrum Disorder, Anxiety Disorders, Somatoform Disorders',\n",
       " 'NCT01453439; Body Dysmorphic Disorder, Obsessive-Compulsive Spectrum Disorder, Anxiety Disorders, Somatoform Disorders',\n",
       " 'NCT01453439; Body Dysmorphic Disorder, Obsessive-Compulsive Spectrum Disorder, Anxiety Disorders, Somatoform Disorders',\n",
       " 'NCT01453439; Body Dysmorphic Disorder, Obsessive-Compulsive Spectrum Disorder, Anxiety Disorders, Somatoform Disorders',\n",
       " 'NCT01453439; Body Dysmorphic Disorder, Obsessive-Compulsive Spectrum Disorder, Anxiety Disorders, Somatoform Disorders',\n",
       " 'NCT01453439; Body Dysmorphic Disorder, Obsessive-Compulsive Spectrum Disorder, Anxiety Disorders, Somatoform Disorders',\n",
       " 'NCT01453439; Body Dysmorphic Disorder, Obsessive-Compulsive Spectrum Disorder, Anxiety Disorders, Somatoform Disorders',\n",
       " 'NCT01453439; Body Dysmorphic Disorder, Obsessive-Compulsive Spectrum Disorder, Anxiety Disorders, Somatoform Disorders',\n",
       " 'NCT02678403; Peripheral Artery Disease',\n",
       " 'NCT02678403; Peripheral Artery Disease',\n",
       " 'NCT01003418; Influenza',\n",
       " 'NCT01003418; Influenza',\n",
       " 'NCT01003418; Influenza',\n",
       " 'NCT01003418; Influenza',\n",
       " 'NCT01003418; Influenza',\n",
       " 'NCT01003418; Influenza',\n",
       " 'NCT03209414; Frail Elderly Syndrome, Coronary Heart Disease, Acute Coronary Syndrome, Coronary Artery Bypass Grafting, Percutaneous Transluminal Coronary Angioplasty',\n",
       " 'NCT03209414; Frail Elderly Syndrome, Coronary Heart Disease, Acute Coronary Syndrome, Coronary Artery Bypass Grafting, Percutaneous Transluminal Coronary Angioplasty',\n",
       " 'NCT03209414; Frail Elderly Syndrome, Coronary Heart Disease, Acute Coronary Syndrome, Coronary Artery Bypass Grafting, Percutaneous Transluminal Coronary Angioplasty',\n",
       " 'NCT03209414; Frail Elderly Syndrome, Coronary Heart Disease, Acute Coronary Syndrome, Coronary Artery Bypass Grafting, Percutaneous Transluminal Coronary Angioplasty',\n",
       " 'NCT03209414; Frail Elderly Syndrome, Coronary Heart Disease, Acute Coronary Syndrome, Coronary Artery Bypass Grafting, Percutaneous Transluminal Coronary Angioplasty',\n",
       " 'NCT03209414; Frail Elderly Syndrome, Coronary Heart Disease, Acute Coronary Syndrome, Coronary Artery Bypass Grafting, Percutaneous Transluminal Coronary Angioplasty',\n",
       " 'NCT03209414; Frail Elderly Syndrome, Coronary Heart Disease, Acute Coronary Syndrome, Coronary Artery Bypass Grafting, Percutaneous Transluminal Coronary Angioplasty',\n",
       " 'NCT03209414; Frail Elderly Syndrome, Coronary Heart Disease, Acute Coronary Syndrome, Coronary Artery Bypass Grafting, Percutaneous Transluminal Coronary Angioplasty',\n",
       " 'NCT03209414; Frail Elderly Syndrome, Coronary Heart Disease, Acute Coronary Syndrome, Coronary Artery Bypass Grafting, Percutaneous Transluminal Coronary Angioplasty',\n",
       " 'NCT03209414; Frail Elderly Syndrome, Coronary Heart Disease, Acute Coronary Syndrome, Coronary Artery Bypass Grafting, Percutaneous Transluminal Coronary Angioplasty',\n",
       " 'NCT03209414; Frail Elderly Syndrome, Coronary Heart Disease, Acute Coronary Syndrome, Coronary Artery Bypass Grafting, Percutaneous Transluminal Coronary Angioplasty',\n",
       " 'NCT03209414; Frail Elderly Syndrome, Coronary Heart Disease, Acute Coronary Syndrome, Coronary Artery Bypass Grafting, Percutaneous Transluminal Coronary Angioplasty',\n",
       " 'NCT03209414; Frail Elderly Syndrome, Coronary Heart Disease, Acute Coronary Syndrome, Coronary Artery Bypass Grafting, Percutaneous Transluminal Coronary Angioplasty',\n",
       " 'NCT04108494; Gastric Cancer',\n",
       " 'NCT04108494; Gastric Cancer',\n",
       " 'NCT01454063; Intraocular Lens Replacement',\n",
       " 'NCT01454063; Intraocular Lens Replacement',\n",
       " 'NCT01454063; Intraocular Lens Replacement',\n",
       " 'NCT01454063; Intraocular Lens Replacement',\n",
       " 'NCT01454063; Intraocular Lens Replacement',\n",
       " 'NCT01454063; Intraocular Lens Replacement',\n",
       " 'NCT01454063; Intraocular Lens Replacement',\n",
       " 'NCT01934101; Arthritis, Rheumatoid',\n",
       " 'NCT01934101; Arthritis, Rheumatoid',\n",
       " 'NCT01934101; Arthritis, Rheumatoid',\n",
       " 'NCT03918499; Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Pathologic Stage IV Gastric Cancer AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Recurrent Gastric Adenocarcinoma, Recurrent Gastroesophageal Junction Adenocarcinoma',\n",
       " 'NCT03918499; Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Pathologic Stage IV Gastric Cancer AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Recurrent Gastric Adenocarcinoma, Recurrent Gastroesophageal Junction Adenocarcinoma',\n",
       " 'NCT03918499; Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Pathologic Stage IV Gastric Cancer AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Recurrent Gastric Adenocarcinoma, Recurrent Gastroesophageal Junction Adenocarcinoma',\n",
       " 'NCT03918499; Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Pathologic Stage IV Gastric Cancer AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Recurrent Gastric Adenocarcinoma, Recurrent Gastroesophageal Junction Adenocarcinoma',\n",
       " 'NCT03154255; Obesity, Childhood',\n",
       " 'NCT03154255; Obesity, Childhood',\n",
       " 'NCT03154255; Obesity, Childhood',\n",
       " 'NCT03154255; Obesity, Childhood',\n",
       " 'NCT03154255; Obesity, Childhood',\n",
       " 'NCT03076762; Bladder Pain Syndrome',\n",
       " 'NCT03076762; Bladder Pain Syndrome',\n",
       " 'NCT03076762; Bladder Pain Syndrome',\n",
       " 'NCT03076762; Bladder Pain Syndrome',\n",
       " 'NCT03076762; Bladder Pain Syndrome',\n",
       " 'NCT03076762; Bladder Pain Syndrome',\n",
       " 'NCT03076762; Bladder Pain Syndrome',\n",
       " 'NCT03412669; Addiction',\n",
       " 'NCT03412669; Addiction',\n",
       " 'NCT03412669; Addiction',\n",
       " 'NCT03412669; Addiction',\n",
       " 'NCT03890770; Renal Impairment, Healthy Volunteer',\n",
       " 'NCT03890770; Renal Impairment, Healthy Volunteer',\n",
       " 'NCT03890770; Renal Impairment, Healthy Volunteer',\n",
       " 'NCT03890770; Renal Impairment, Healthy Volunteer',\n",
       " 'NCT03890770; Renal Impairment, Healthy Volunteer',\n",
       " 'NCT01610245; Influenza',\n",
       " 'NCT01610245; Influenza',\n",
       " 'NCT03761888; Preeclampsia Severe',\n",
       " 'NCT03761888; Preeclampsia Severe',\n",
       " 'NCT03761888; Preeclampsia Severe',\n",
       " 'NCT03761888; Preeclampsia Severe',\n",
       " 'NCT03761888; Preeclampsia Severe',\n",
       " 'NCT03761888; Preeclampsia Severe',\n",
       " 'NCT00199043; Adult Acute Lymphocytic Leukemia, High-Grade Lymphoma',\n",
       " 'NCT00199043; Adult Acute Lymphocytic Leukemia, High-Grade Lymphoma',\n",
       " 'NCT03582982; Chronic Kidney Disease stage3, Chronic Kidney Disease stage4',\n",
       " 'NCT03582982; Chronic Kidney Disease stage3, Chronic Kidney Disease stage4',\n",
       " 'NCT03582982; Chronic Kidney Disease stage3, Chronic Kidney Disease stage4',\n",
       " 'NCT03582982; Chronic Kidney Disease stage3, Chronic Kidney Disease stage4',\n",
       " 'NCT03582982; Chronic Kidney Disease stage3, Chronic Kidney Disease stage4',\n",
       " 'NCT03582982; Chronic Kidney Disease stage3, Chronic Kidney Disease stage4',\n",
       " 'NCT03582982; Chronic Kidney Disease stage3, Chronic Kidney Disease stage4',\n",
       " 'NCT03582982; Chronic Kidney Disease stage3, Chronic Kidney Disease stage4',\n",
       " 'NCT03582982; Chronic Kidney Disease stage3, Chronic Kidney Disease stage4',\n",
       " 'NCT03582982; Chronic Kidney Disease stage3, Chronic Kidney Disease stage4',\n",
       " 'NCT03582982; Chronic Kidney Disease stage3, Chronic Kidney Disease stage4',\n",
       " 'NCT03582982; Chronic Kidney Disease stage3, Chronic Kidney Disease stage4',\n",
       " 'NCT03582982; Chronic Kidney Disease stage3, Chronic Kidney Disease stage4',\n",
       " 'NCT03582982; Chronic Kidney Disease stage3, Chronic Kidney Disease stage4',\n",
       " 'NCT03582982; Chronic Kidney Disease stage3, Chronic Kidney Disease stage4',\n",
       " 'NCT02710877; Labor Pain',\n",
       " 'NCT02710877; Labor Pain',\n",
       " 'NCT02710877; Labor Pain',\n",
       " 'NCT02710877; Labor Pain',\n",
       " 'NCT02710877; Labor Pain',\n",
       " 'NCT02710877; Labor Pain',\n",
       " 'NCT02710877; Labor Pain',\n",
       " 'NCT02970929; Schizophrenia',\n",
       " 'NCT02970929; Schizophrenia',\n",
       " 'NCT02970929; Schizophrenia',\n",
       " 'NCT02970929; Schizophrenia',\n",
       " 'NCT02970929; Schizophrenia',\n",
       " 'NCT02970929; Schizophrenia',\n",
       " 'NCT02970929; Schizophrenia',\n",
       " 'NCT02970929; Schizophrenia',\n",
       " 'NCT02970929; Schizophrenia',\n",
       " 'NCT02970929; Schizophrenia',\n",
       " 'NCT02970929; Schizophrenia',\n",
       " 'NCT02970929; Schizophrenia',\n",
       " 'NCT02970929; Schizophrenia',\n",
       " 'NCT02970929; Schizophrenia',\n",
       " 'NCT02970929; Schizophrenia',\n",
       " 'NCT02970929; Schizophrenia',\n",
       " 'NCT02970929; Schizophrenia',\n",
       " 'NCT02970929; Schizophrenia',\n",
       " 'NCT02970929; Schizophrenia',\n",
       " 'NCT02970929; Schizophrenia',\n",
       " 'NCT02970929; Schizophrenia',\n",
       " 'NCT02970929; Schizophrenia',\n",
       " 'NCT02970929; Schizophrenia',\n",
       " 'NCT02970929; Schizophrenia',\n",
       " 'NCT02970929; Schizophrenia',\n",
       " 'NCT02970929; Schizophrenia',\n",
       " 'NCT02970929; Schizophrenia',\n",
       " 'NCT02970929; Schizophrenia',\n",
       " 'NCT02970929; Schizophrenia',\n",
       " 'NCT02970929; Schizophrenia',\n",
       " 'NCT02970929; Schizophrenia',\n",
       " 'NCT02970929; Schizophrenia',\n",
       " 'NCT02970929; Schizophrenia',\n",
       " 'NCT02970929; Schizophrenia',\n",
       " 'NCT01472471; Childhood Asthma, Oxidative Stress',\n",
       " 'NCT01472471; Childhood Asthma, Oxidative Stress',\n",
       " 'NCT00505037; Hyperphosphatemia, Chronic Kidney Disease',\n",
       " 'NCT00505037; Hyperphosphatemia, Chronic Kidney Disease',\n",
       " 'NCT00505037; Hyperphosphatemia, Chronic Kidney Disease',\n",
       " 'NCT00505037; Hyperphosphatemia, Chronic Kidney Disease',\n",
       " 'NCT00505037; Hyperphosphatemia, Chronic Kidney Disease',\n",
       " 'NCT00505037; Hyperphosphatemia, Chronic Kidney Disease',\n",
       " 'NCT03931473; Malaria, Anemia',\n",
       " 'NCT03931473; Malaria, Anemia',\n",
       " 'NCT03931473; Malaria, Anemia',\n",
       " 'NCT00313625; Multiple Myeloma and Plasma Cell Neoplasm',\n",
       " 'NCT00313625; Multiple Myeloma and Plasma Cell Neoplasm',\n",
       " 'NCT00313625; Multiple Myeloma and Plasma Cell Neoplasm',\n",
       " 'NCT00313625; Multiple Myeloma and Plasma Cell Neoplasm',\n",
       " 'NCT03759197; Plaque Psoriasis',\n",
       " 'NCT03759197; Plaque Psoriasis',\n",
       " 'NCT03759197; Plaque Psoriasis',\n",
       " 'NCT03759197; Plaque Psoriasis',\n",
       " 'NCT02193906; Cognitive Dysfunction',\n",
       " 'NCT02193906; Cognitive Dysfunction',\n",
       " 'NCT02193906; Cognitive Dysfunction',\n",
       " 'NCT02193906; Cognitive Dysfunction',\n",
       " 'NCT02193906; Cognitive Dysfunction',\n",
       " 'NCT02193906; Cognitive Dysfunction',\n",
       " 'NCT02193906; Cognitive Dysfunction',\n",
       " 'NCT02324296; Small Cell Lung Cancer',\n",
       " 'NCT02324296; Small Cell Lung Cancer',\n",
       " 'NCT02324296; Small Cell Lung Cancer',\n",
       " 'NCT02324296; Small Cell Lung Cancer',\n",
       " 'NCT01572181; Hematologic Malignancy',\n",
       " 'NCT01572181; Hematologic Malignancy',\n",
       " 'NCT01572181; Hematologic Malignancy',\n",
       " 'NCT01572181; Hematologic Malignancy',\n",
       " 'NCT01572181; Hematologic Malignancy',\n",
       " 'NCT01572181; Hematologic Malignancy',\n",
       " 'NCT00632996; Shoulder Impingement Syndrome',\n",
       " 'NCT00632996; Shoulder Impingement Syndrome',\n",
       " 'NCT00632996; Shoulder Impingement Syndrome',\n",
       " 'NCT00632996; Shoulder Impingement Syndrome',\n",
       " 'NCT00632996; Shoulder Impingement Syndrome',\n",
       " 'NCT00632996; Shoulder Impingement Syndrome',\n",
       " 'NCT03378336; Psoriatic Arthritis',\n",
       " 'NCT03378336; Psoriatic Arthritis',\n",
       " 'NCT03378336; Psoriatic Arthritis',\n",
       " 'NCT03378336; Psoriatic Arthritis',\n",
       " 'NCT03378336; Psoriatic Arthritis',\n",
       " 'NCT03378336; Psoriatic Arthritis',\n",
       " 'NCT03378336; Psoriatic Arthritis',\n",
       " 'NCT03378336; Psoriatic Arthritis',\n",
       " 'NCT03378336; Psoriatic Arthritis',\n",
       " 'NCT02745054; Blood Coagulation',\n",
       " 'NCT02745054; Blood Coagulation',\n",
       " 'NCT02745054; Blood Coagulation',\n",
       " 'NCT02745054; Blood Coagulation',\n",
       " 'NCT02745054; Blood Coagulation',\n",
       " 'NCT02745054; Blood Coagulation',\n",
       " 'NCT02745054; Blood Coagulation',\n",
       " 'NCT02342600; Gastrointestinal Stromal Tumors',\n",
       " 'NCT02342600; Gastrointestinal Stromal Tumors',\n",
       " 'NCT02342600; Gastrointestinal Stromal Tumors',\n",
       " 'NCT02342600; Gastrointestinal Stromal Tumors',\n",
       " 'NCT02013336; Recurrent or Refractory Solid Tumors, Ewing Sarcoma, Rhabdomyosarcoma, Neuroblastoma, Osteosarcoma',\n",
       " 'NCT02013336; Recurrent or Refractory Solid Tumors, Ewing Sarcoma, Rhabdomyosarcoma, Neuroblastoma, Osteosarcoma',\n",
       " 'NCT03467178; Recurrent, Platinum-resistant Ovarian Cancer',\n",
       " 'NCT03467178; Recurrent, Platinum-resistant Ovarian Cancer',\n",
       " 'NCT03467178; Recurrent, Platinum-resistant Ovarian Cancer',\n",
       " 'NCT03467178; Recurrent, Platinum-resistant Ovarian Cancer',\n",
       " 'NCT03467178; Recurrent, Platinum-resistant Ovarian Cancer',\n",
       " 'NCT03467178; Recurrent, Platinum-resistant Ovarian Cancer',\n",
       " 'NCT03467178; Recurrent, Platinum-resistant Ovarian Cancer',\n",
       " 'NCT03467178; Recurrent, Platinum-resistant Ovarian Cancer',\n",
       " 'NCT03467178; Recurrent, Platinum-resistant Ovarian Cancer',\n",
       " 'NCT03467178; Recurrent, Platinum-resistant Ovarian Cancer',\n",
       " 'NCT03361111; Severe Asthma',\n",
       " 'NCT03361111; Severe Asthma',\n",
       " 'NCT03361111; Severe Asthma',\n",
       " 'NCT03361111; Severe Asthma',\n",
       " 'NCT03361111; Severe Asthma',\n",
       " 'NCT03361111; Severe Asthma',\n",
       " 'NCT03361111; Severe Asthma',\n",
       " 'NCT03361111; Severe Asthma',\n",
       " 'NCT03361111; Severe Asthma',\n",
       " \"NCT02994719; Parkinson's Disease, Parkinsonian Disorders, Atypical Parkinson Disease, Progressive Supranuclear Palsy, Multiple System Atrophy, Corticobasal Degeneration, Gait, Frontal, Huntington Disease\",\n",
       " \"NCT02994719; Parkinson's Disease, Parkinsonian Disorders, Atypical Parkinson Disease, Progressive Supranuclear Palsy, Multiple System Atrophy, Corticobasal Degeneration, Gait, Frontal, Huntington Disease\",\n",
       " \"NCT02994719; Parkinson's Disease, Parkinsonian Disorders, Atypical Parkinson Disease, Progressive Supranuclear Palsy, Multiple System Atrophy, Corticobasal Degeneration, Gait, Frontal, Huntington Disease\",\n",
       " \"NCT02994719; Parkinson's Disease, Parkinsonian Disorders, Atypical Parkinson Disease, Progressive Supranuclear Palsy, Multiple System Atrophy, Corticobasal Degeneration, Gait, Frontal, Huntington Disease\",\n",
       " \"NCT02994719; Parkinson's Disease, Parkinsonian Disorders, Atypical Parkinson Disease, Progressive Supranuclear Palsy, Multiple System Atrophy, Corticobasal Degeneration, Gait, Frontal, Huntington Disease\",\n",
       " \"NCT01388933; Crohn's Disease\",\n",
       " \"NCT01388933; Crohn's Disease\",\n",
       " \"NCT01388933; Crohn's Disease\",\n",
       " \"NCT01388933; Crohn's Disease\",\n",
       " \"NCT01388933; Crohn's Disease\",\n",
       " \"NCT01388933; Crohn's Disease\",\n",
       " \"NCT01388933; Crohn's Disease\",\n",
       " 'NCT02629614; Essential Tremor',\n",
       " 'NCT02629614; Essential Tremor',\n",
       " 'NCT02629614; Essential Tremor',\n",
       " 'NCT04021147; Exercise, Pain',\n",
       " 'NCT04021147; Exercise, Pain',\n",
       " 'NCT04021147; Exercise, Pain',\n",
       " 'NCT04021147; Exercise, Pain',\n",
       " 'NCT04021147; Exercise, Pain',\n",
       " 'NCT03805425; Hyperopia',\n",
       " 'NCT03805425; Hyperopia',\n",
       " 'NCT03805425; Hyperopia',\n",
       " 'NCT03805425; Hyperopia',\n",
       " 'NCT03805425; Hyperopia',\n",
       " 'NCT03805425; Hyperopia',\n",
       " 'NCT03805425; Hyperopia',\n",
       " 'NCT03805425; Hyperopia',\n",
       " 'NCT02931890; Gastric Cancer',\n",
       " 'NCT02931890; Gastric Cancer',\n",
       " 'NCT02931890; Gastric Cancer',\n",
       " 'NCT02931890; Gastric Cancer',\n",
       " 'NCT01362790; Mesothelioma, Adenocarcinoma of Lung, Pancreatic Neoplasms',\n",
       " 'NCT01362790; Mesothelioma, Adenocarcinoma of Lung, Pancreatic Neoplasms',\n",
       " 'NCT01362790; Mesothelioma, Adenocarcinoma of Lung, Pancreatic Neoplasms',\n",
       " 'NCT01362790; Mesothelioma, Adenocarcinoma of Lung, Pancreatic Neoplasms',\n",
       " 'NCT01362790; Mesothelioma, Adenocarcinoma of Lung, Pancreatic Neoplasms',\n",
       " 'NCT01362790; Mesothelioma, Adenocarcinoma of Lung, Pancreatic Neoplasms',\n",
       " 'NCT01362790; Mesothelioma, Adenocarcinoma of Lung, Pancreatic Neoplasms',\n",
       " 'NCT04229225; Knee Osteoarthritis',\n",
       " 'NCT04229225; Knee Osteoarthritis',\n",
       " 'NCT04229225; Knee Osteoarthritis',\n",
       " 'NCT04229225; Knee Osteoarthritis',\n",
       " 'NCT04229225; Knee Osteoarthritis',\n",
       " 'NCT04229225; Knee Osteoarthritis',\n",
       " 'NCT03638687; Post Partum Depression, Bipolar Disorder',\n",
       " 'NCT03638687; Post Partum Depression, Bipolar Disorder',\n",
       " 'NCT01938326; Early Gastric Cancer',\n",
       " 'NCT01938326; Early Gastric Cancer',\n",
       " 'NCT01938326; Early Gastric Cancer',\n",
       " 'NCT01938326; Early Gastric Cancer',\n",
       " 'NCT01938326; Early Gastric Cancer',\n",
       " 'NCT01938326; Early Gastric Cancer',\n",
       " 'NCT01938326; Early Gastric Cancer',\n",
       " 'NCT01938326; Early Gastric Cancer',\n",
       " 'NCT01938326; Early Gastric Cancer',\n",
       " 'NCT01938326; Early Gastric Cancer',\n",
       " 'NCT01938326; Early Gastric Cancer',\n",
       " 'NCT01938326; Early Gastric Cancer',\n",
       " 'NCT01938326; Early Gastric Cancer',\n",
       " 'NCT01938326; Early Gastric Cancer',\n",
       " 'NCT01938326; Early Gastric Cancer',\n",
       " 'NCT01938326; Early Gastric Cancer',\n",
       " 'NCT01092611; AIDS',\n",
       " 'NCT01092611; AIDS',\n",
       " 'NCT01092611; AIDS',\n",
       " 'NCT01092611; AIDS',\n",
       " 'NCT01092611; AIDS',\n",
       " 'NCT01092611; AIDS',\n",
       " 'NCT01092611; AIDS',\n",
       " 'NCT01092611; AIDS',\n",
       " 'NCT01092611; AIDS',\n",
       " 'NCT01092611; AIDS',\n",
       " 'NCT01092611; AIDS',\n",
       " 'NCT01092611; AIDS',\n",
       " 'NCT01092611; AIDS',\n",
       " 'NCT01092611; AIDS',\n",
       " 'NCT01092611; AIDS',\n",
       " 'NCT01092611; AIDS',\n",
       " 'NCT01092611; AIDS',\n",
       " 'NCT03197909; Chronic Obstructive Pulmonary',\n",
       " 'NCT03197909; Chronic Obstructive Pulmonary',\n",
       " 'NCT00704470; Performance in Simulated Emergencies, Stress During Simulator Scenario, Behaviour of Physicians in Simulated Emergencies',\n",
       " 'NCT00704470; Performance in Simulated Emergencies, Stress During Simulator Scenario, Behaviour of Physicians in Simulated Emergencies',\n",
       " 'NCT04105374; Anaplastic Astrocytoma, Glioblastoma, Oligodendroglioma, Supratentorial Glioblastoma',\n",
       " 'NCT04105374; Anaplastic Astrocytoma, Glioblastoma, Oligodendroglioma, Supratentorial Glioblastoma',\n",
       " 'NCT04105374; Anaplastic Astrocytoma, Glioblastoma, Oligodendroglioma, Supratentorial Glioblastoma',\n",
       " 'NCT04105374; Anaplastic Astrocytoma, Glioblastoma, Oligodendroglioma, Supratentorial Glioblastoma',\n",
       " 'NCT04105374; Anaplastic Astrocytoma, Glioblastoma, Oligodendroglioma, Supratentorial Glioblastoma',\n",
       " 'NCT04105374; Anaplastic Astrocytoma, Glioblastoma, Oligodendroglioma, Supratentorial Glioblastoma',\n",
       " 'NCT02905006; Chronic Plaque Psoriasis',\n",
       " 'NCT02905006; Chronic Plaque Psoriasis',\n",
       " 'NCT02905006; Chronic Plaque Psoriasis',\n",
       " 'NCT02905006; Chronic Plaque Psoriasis',\n",
       " 'NCT02905006; Chronic Plaque Psoriasis',\n",
       " 'NCT02905006; Chronic Plaque Psoriasis',\n",
       " 'NCT01244698; Bacterial Infection, Anti-infective Agents, Breast Implantation',\n",
       " 'NCT01244698; Bacterial Infection, Anti-infective Agents, Breast Implantation',\n",
       " 'NCT01244698; Bacterial Infection, Anti-infective Agents, Breast Implantation',\n",
       " 'NCT01244698; Bacterial Infection, Anti-infective Agents, Breast Implantation',\n",
       " 'NCT01244698; Bacterial Infection, Anti-infective Agents, Breast Implantation',\n",
       " 'NCT01244698; Bacterial Infection, Anti-infective Agents, Breast Implantation',\n",
       " 'NCT03246633; Lesion; Pigment, Diagnostic Self Evaluation',\n",
       " 'NCT03246633; Lesion; Pigment, Diagnostic Self Evaluation',\n",
       " 'NCT02278159; Kidney Failure, Chronic',\n",
       " 'NCT02278159; Kidney Failure, Chronic',\n",
       " 'NCT02278159; Kidney Failure, Chronic',\n",
       " 'NCT03885453; Panic Disorder, Panic Disorder With Agoraphobia, Agoraphobia, Agoraphobia With Panic Attacks, Depression',\n",
       " 'NCT03885453; Panic Disorder, Panic Disorder With Agoraphobia, Agoraphobia, Agoraphobia With Panic Attacks, Depression',\n",
       " 'NCT03885453; Panic Disorder, Panic Disorder With Agoraphobia, Agoraphobia, Agoraphobia With Panic Attacks, Depression',\n",
       " 'NCT03885453; Panic Disorder, Panic Disorder With Agoraphobia, Agoraphobia, Agoraphobia With Panic Attacks, Depression',\n",
       " 'NCT03885453; Panic Disorder, Panic Disorder With Agoraphobia, Agoraphobia, Agoraphobia With Panic Attacks, Depression',\n",
       " 'NCT03885453; Panic Disorder, Panic Disorder With Agoraphobia, Agoraphobia, Agoraphobia With Panic Attacks, Depression',\n",
       " 'NCT03885453; Panic Disorder, Panic Disorder With Agoraphobia, Agoraphobia, Agoraphobia With Panic Attacks, Depression',\n",
       " 'NCT03885453; Panic Disorder, Panic Disorder With Agoraphobia, Agoraphobia, Agoraphobia With Panic Attacks, Depression',\n",
       " 'NCT03885453; Panic Disorder, Panic Disorder With Agoraphobia, Agoraphobia, Agoraphobia With Panic Attacks, Depression',\n",
       " 'NCT03885453; Panic Disorder, Panic Disorder With Agoraphobia, Agoraphobia, Agoraphobia With Panic Attacks, Depression',\n",
       " 'NCT03252002; Healthy Volunteer',\n",
       " 'NCT03252002; Healthy Volunteer',\n",
       " 'NCT03252002; Healthy Volunteer',\n",
       " 'NCT03252002; Healthy Volunteer',\n",
       " 'NCT03252002; Healthy Volunteer',\n",
       " 'NCT03252002; Healthy Volunteer',\n",
       " 'NCT03252002; Healthy Volunteer',\n",
       " 'NCT03252002; Healthy Volunteer',\n",
       " 'NCT03252002; Healthy Volunteer',\n",
       " 'NCT00922961; Breast Cancer',\n",
       " 'NCT00922961; Breast Cancer',\n",
       " 'NCT00922961; Breast Cancer',\n",
       " 'NCT00922961; Breast Cancer',\n",
       " 'NCT00922961; Breast Cancer',\n",
       " 'NCT00922961; Breast Cancer',\n",
       " 'NCT01669291; Fertility',\n",
       " 'NCT01669291; Fertility',\n",
       " 'NCT01669291; Fertility',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03650244; Urinary Incontinence,Stress',\n",
       " 'NCT03234699; Healthy',\n",
       " 'NCT03234699; Healthy',\n",
       " 'NCT03234699; Healthy',\n",
       " 'NCT03234699; Healthy',\n",
       " 'NCT03234699; Healthy',\n",
       " 'NCT03234699; Healthy',\n",
       " 'NCT02084004; Type 2 Diabetes Mellitus',\n",
       " 'NCT02084004; Type 2 Diabetes Mellitus',\n",
       " 'NCT02084004; Type 2 Diabetes Mellitus',\n",
       " 'NCT02084004; Type 2 Diabetes Mellitus',\n",
       " 'NCT02084004; Type 2 Diabetes Mellitus',\n",
       " 'NCT03318952; Anesthesia, Dental, Pain, Postoperative',\n",
       " 'NCT03318952; Anesthesia, Dental, Pain, Postoperative',\n",
       " 'NCT03318952; Anesthesia, Dental, Pain, Postoperative',\n",
       " 'NCT03318952; Anesthesia, Dental, Pain, Postoperative',\n",
       " 'NCT03318952; Anesthesia, Dental, Pain, Postoperative',\n",
       " 'NCT03318952; Anesthesia, Dental, Pain, Postoperative',\n",
       " 'NCT03318952; Anesthesia, Dental, Pain, Postoperative',\n",
       " 'NCT03667690; Candidemia, Mycoses, Fungal Infection, Invasive Candidiases',\n",
       " 'NCT03667690; Candidemia, Mycoses, Fungal Infection, Invasive Candidiases',\n",
       " 'NCT03667690; Candidemia, Mycoses, Fungal Infection, Invasive Candidiases',\n",
       " 'NCT03667690; Candidemia, Mycoses, Fungal Infection, Invasive Candidiases',\n",
       " 'NCT03667690; Candidemia, Mycoses, Fungal Infection, Invasive Candidiases',\n",
       " 'NCT03667690; Candidemia, Mycoses, Fungal Infection, Invasive Candidiases',\n",
       " 'NCT03667690; Candidemia, Mycoses, Fungal Infection, Invasive Candidiases',\n",
       " 'NCT03667690; Candidemia, Mycoses, Fungal Infection, Invasive Candidiases',\n",
       " 'NCT03667690; Candidemia, Mycoses, Fungal Infection, Invasive Candidiases',\n",
       " 'NCT03667690; Candidemia, Mycoses, Fungal Infection, Invasive Candidiases',\n",
       " 'NCT03667690; Candidemia, Mycoses, Fungal Infection, Invasive Candidiases',\n",
       " 'NCT03667690; Candidemia, Mycoses, Fungal Infection, Invasive Candidiases',\n",
       " 'NCT03667690; Candidemia, Mycoses, Fungal Infection, Invasive Candidiases',\n",
       " 'NCT03667690; Candidemia, Mycoses, Fungal Infection, Invasive Candidiases',\n",
       " 'NCT03667690; Candidemia, Mycoses, Fungal Infection, Invasive Candidiases',\n",
       " 'NCT03667690; Candidemia, Mycoses, Fungal Infection, Invasive Candidiases',\n",
       " 'NCT03667690; Candidemia, Mycoses, Fungal Infection, Invasive Candidiases',\n",
       " 'NCT03667690; Candidemia, Mycoses, Fungal Infection, Invasive Candidiases',\n",
       " 'NCT03667690; Candidemia, Mycoses, Fungal Infection, Invasive Candidiases',\n",
       " 'NCT03667690; Candidemia, Mycoses, Fungal Infection, Invasive Candidiases',\n",
       " 'NCT03667690; Candidemia, Mycoses, Fungal Infection, Invasive Candidiases',\n",
       " 'NCT03667690; Candidemia, Mycoses, Fungal Infection, Invasive Candidiases',\n",
       " 'NCT03574519; Physical Activity, Sedentary Lifestyle, Overweight and Obesity',\n",
       " 'NCT03574519; Physical Activity, Sedentary Lifestyle, Overweight and Obesity',\n",
       " 'NCT03574519; Physical Activity, Sedentary Lifestyle, Overweight and Obesity',\n",
       " 'NCT01077050; Malignant Melanoma',\n",
       " 'NCT01077050; Malignant Melanoma',\n",
       " 'NCT01361698; Schizophrenia, Bipolar Disorder',\n",
       " 'NCT01361698; Schizophrenia, Bipolar Disorder',\n",
       " 'NCT01361698; Schizophrenia, Bipolar Disorder',\n",
       " 'NCT01361698; Schizophrenia, Bipolar Disorder',\n",
       " 'NCT01361698; Schizophrenia, Bipolar Disorder',\n",
       " 'NCT01361698; Schizophrenia, Bipolar Disorder',\n",
       " 'NCT01361698; Schizophrenia, Bipolar Disorder',\n",
       " 'NCT01361698; Schizophrenia, Bipolar Disorder',\n",
       " 'NCT00936546; Debilitating Fibrosing Skin Disorders (Localised Scleroderma, Eosinophilic Fasciitis)',\n",
       " 'NCT00936546; Debilitating Fibrosing Skin Disorders (Localised Scleroderma, Eosinophilic Fasciitis)',\n",
       " 'NCT00409942; Congestive Heart Failure',\n",
       " 'NCT00409942; Congestive Heart Failure',\n",
       " 'NCT00409942; Congestive Heart Failure',\n",
       " 'NCT00409942; Congestive Heart Failure',\n",
       " 'NCT00409942; Congestive Heart Failure',\n",
       " 'NCT00409942; Congestive Heart Failure',\n",
       " 'NCT00409942; Congestive Heart Failure',\n",
       " 'NCT00374569; Gymnastics Injury, Motor Learning, Balance',\n",
       " 'NCT00374569; Gymnastics Injury, Motor Learning, Balance',\n",
       " 'NCT02416271; Osteoporosis',\n",
       " 'NCT02416271; Osteoporosis',\n",
       " 'NCT02416271; Osteoporosis',\n",
       " 'NCT02416271; Osteoporosis',\n",
       " 'NCT02416271; Osteoporosis',\n",
       " 'NCT02416271; Osteoporosis',\n",
       " 'NCT02416271; Osteoporosis',\n",
       " 'NCT02416271; Osteoporosis',\n",
       " 'NCT02416271; Osteoporosis',\n",
       " 'NCT02416271; Osteoporosis',\n",
       " 'NCT02416271; Osteoporosis',\n",
       " 'NCT02416271; Osteoporosis',\n",
       " 'NCT02416271; Osteoporosis',\n",
       " 'NCT00613600; Overweight, Obesity',\n",
       " 'NCT00613600; Overweight, Obesity',\n",
       " 'NCT00613600; Overweight, Obesity',\n",
       " 'NCT00613600; Overweight, Obesity',\n",
       " 'NCT00613600; Overweight, Obesity',\n",
       " 'NCT00613600; Overweight, Obesity',\n",
       " 'NCT00613600; Overweight, Obesity',\n",
       " 'NCT00613600; Overweight, Obesity',\n",
       " 'NCT00613600; Overweight, Obesity',\n",
       " 'NCT00613600; Overweight, Obesity',\n",
       " 'NCT00395382; Vascular Calcification, Arteriosclerosis',\n",
       " 'NCT00395382; Vascular Calcification, Arteriosclerosis',\n",
       " 'NCT00395382; Vascular Calcification, Arteriosclerosis',\n",
       " 'NCT00395382; Vascular Calcification, Arteriosclerosis',\n",
       " 'NCT00395382; Vascular Calcification, Arteriosclerosis',\n",
       " 'NCT00395382; Vascular Calcification, Arteriosclerosis',\n",
       " 'NCT00395382; Vascular Calcification, Arteriosclerosis',\n",
       " 'NCT00395382; Vascular Calcification, Arteriosclerosis',\n",
       " 'NCT00517322; Left Atrial Volume, Hypertensive Heart Disease, Antihypertensive Drugs, Diastolic Function, Renin Angiotensin System',\n",
       " 'NCT00517322; Left Atrial Volume, Hypertensive Heart Disease, Antihypertensive Drugs, Diastolic Function, Renin Angiotensin System',\n",
       " 'NCT00517322; Left Atrial Volume, Hypertensive Heart Disease, Antihypertensive Drugs, Diastolic Function, Renin Angiotensin System',\n",
       " 'NCT02184481; Depression',\n",
       " 'NCT02184481; Depression',\n",
       " 'NCT02067169; Transplant Recipients With CMV Infection',\n",
       " 'NCT02067169; Transplant Recipients With CMV Infection',\n",
       " 'NCT01292096; Hospitalization, Patient Readmission',\n",
       " 'NCT01292096; Hospitalization, Patient Readmission',\n",
       " ...]"
      ]
     },
     "execution_count": 116,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "cls.tag_corpus['NCT']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 115,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['Time from randomization to the first event of cardiovascular death, resuscitated cardiac arrest, acute myocardial infarction, stroke, or urgent hospitalization for angina requiring coronary revascularization',\n",
       " 'Time from randomization to death (total mortality)',\n",
       " 'Time from randomization to cardiovascular death',\n",
       " 'Time from randomization to resuscitated cardiac arrest',\n",
       " 'Time from randomization to myocardial infarction',\n",
       " 'Time from randomization to stroke',\n",
       " 'Time from randomization to urgent hospitalization for angina requiring coronary revascularization',\n",
       " 'Time from randomization to the first event of cardiovascular death, resuscitated cardiac arrest, acute MI or stroke.',\n",
       " 'Changes in Sleep quality during acute uncomplicated diverticulitis from baseline score at remission (14th, 21st and 30th day)',\n",
       " 'Changes in Sleepiness during acute uncomplicated diverticulitis from baseline score at remission (14th, 21st and 30th day)',\n",
       " 'Changes in fatigue during acute uncomplicated diverticulitis from baseline score at remission (14th, 21st and 30th day)',\n",
       " 'Changes in general well-being during acute uncomplicated diverticulitis from baseline score at remission (14th, 21st and 30th day)',\n",
       " 'Changes in pain during acute uncomplicated diverticulitis from baseline score at remission (14th, 21st and 30th day)',\n",
       " 'accuracy of sleep diary compared to actigraph in measuring sleep data',\n",
       " 'accuracy of sleep diary compared to Polysomnography (PSG) in measuring sleep data',\n",
       " \"correlation between fatigue and level of cytokines in patient's plasma\",\n",
       " \"correlation between pain and level of cytokines in patient's plasma\",\n",
       " \"correlation between sleepiness and level of cytokines in patient's plasma\",\n",
       " \"correlation between general well-being and level of cytokines in patient's plasma\",\n",
       " 'Change from Baseline in Perceived stress at the end of the stress managements programs',\n",
       " 'the profile of mood states (POMS)',\n",
       " 'the Freiburg Mindfulness Inventory-14',\n",
       " 'the Spielberger State-Trait-Anxiety Inventory (S-STAI)',\n",
       " 'heart rate variability',\n",
       " 'salivary cortisol',\n",
       " 'salivary immunoglobulin A',\n",
       " 'urinary catecholamines',\n",
       " 'Reduction of local-regional failure rate',\n",
       " 'Progression-Free Survival',\n",
       " 'Overall Survival',\n",
       " 'Grade 3-5 Toxicity Rate',\n",
       " 'Quality of Life FACT-L',\n",
       " 'Quality of Life EQ-5D',\n",
       " 'Dose-Response Characterization',\n",
       " 'Dose Escalation Feasibility',\n",
       " 'Imaging Use',\n",
       " 'Clinical remission 12 months after initiation of VNS',\n",
       " 'Clinical remission 6 months after initiation of VNS',\n",
       " 'VNS tolerance',\n",
       " 'Assessment of VNS effectiveness with biological markers',\n",
       " 'Endoscopic and ultrasound Assessment of VNS effectiveness',\n",
       " 'Assessment of the central effects of VNS',\n",
       " 'Evaluation of peripheral effects of VNS on sympatho-vagal balance',\n",
       " 'Percent of subjects abstinent from heavy drinking',\n",
       " 'Percent of subjects abstinent from any drinking',\n",
       " 'Percent of days abstinent from heavy drinking',\n",
       " 'Percent of days abstinent from any alcohol',\n",
       " 'Number of drinks per drinking day',\n",
       " 'Days to relapse to first heavy drinking day',\n",
       " 'Incidence of Adverse Events',\n",
       " 'Number of participants with adverse events',\n",
       " 'To evaluate the effect of depsipeptide therapy on performance status as measured by the Karnofsky score assessment',\n",
       " 'To evaluate the time to objective disease progression.',\n",
       " 'Overall survival at 12 months of patients last randomized and at 48 months of patients first randomized',\n",
       " 'Complete resection rate',\n",
       " 'Quality of survival in the different treatments selected on the basis of staging at 1, 3, 6, 12, 18, and 24 months by EuroQol EQ-5D, EORTC core module QLQ-C30, EORTC esophageal module QLQ-OES24, and EORTC gastric module QLQ-STO22',\n",
       " 'Health resource utilization, including the selection of treatments and subsequent use of health service resources',\n",
       " 'Change in HBA1-c levels',\n",
       " '24 hour mean blood pressure',\n",
       " 'plasma glucose',\n",
       " 'HOMA',\n",
       " 'Requirement for the use of extra stomal appliances',\n",
       " 'Quality of life',\n",
       " 'Frequency of soiling in 24 hours.',\n",
       " 'Cost analysis',\n",
       " '20% Reduction in Lesion Size at 48 to 72 Hours Compared to Baseline in All Randomized Patients.',\n",
       " 'Resolution or Near Resolution of Lesion at Test of Cure Visit',\n",
       " 'A data-bank of measured changes in lung dynamics at various clinical settings acquired by the chest sensors.',\n",
       " 'Detection of changes in lung ventilation by the novel system. Feasibility study. Comparison of the detection made by the novel system to the conventional monitoring methods in use.',\n",
       " '\"Relevant\" or \"Not relevant\" for orthopedic assessment',\n",
       " 'Knee Injury an Osteoarhtritis Outcome Score (KOOS)',\n",
       " 'Bone microarchitecture of the distal radius',\n",
       " 'Bone microarchitecture of the distal radius',\n",
       " 'Bone microarchitecture of the distal radius',\n",
       " 'Bone microarchitecture of the distal radius',\n",
       " 'Bone microarchitecture of the distal radius',\n",
       " 'Bone microarchitecture of the distal radius',\n",
       " 'Change in Musculoskeletal Symptom Sub-scale on the Breast Cancer Prevention Trial Symptom Scale',\n",
       " 'Change in Hand Grip Strength',\n",
       " 'Change in PROMIS Physical Functioning Questionnaire',\n",
       " 'Average Percent Adherence to Vitamin D Interventio',\n",
       " 'Serum Estradiol Concentrations',\n",
       " 'Change in Steady State Concentrations of Serum Anastrazole and Letrozole',\n",
       " 'Whole Body Bone Mineral Density',\n",
       " 'Vitamin D Binding Protein Genotype',\n",
       " 'Phrmacokinetics of RO49958855 (parent molecule) and metabolites following multiple doses of RO5024048: AUC, Cmax, Tmax T1/2, Ae, Cl',\n",
       " 'Effect of renal impairment on safety and tolerability: Adverse events, vital signs, ECG, laboratory parameters',\n",
       " 'Number of drug use instances',\n",
       " 'Positive drug assays',\n",
       " 'Number of HIV transmission risk events',\n",
       " 'Positive sexually transmitted infection (STI) test',\n",
       " 'Communication skills',\n",
       " 'Perfused small vessel density',\n",
       " 'Total small vessel density',\n",
       " 'Endocan level',\n",
       " 'Microvascular flow index',\n",
       " 'Oropharyngeal (airway) leak pressure - Initial',\n",
       " 'Oropharyngeal (airway) leak pressure - 10 Minutes',\n",
       " 'Time for Successful Placement of the Supraglottic Airway',\n",
       " 'Number of attempts to placement of Supraglottic Airway',\n",
       " 'Fiberoptic Grade of Laryngeal View through Supraglottic Airway',\n",
       " 'Gastric Tube Insertion Ease of Placement',\n",
       " 'Gastric Tube Insertion Time',\n",
       " 'Gastric Tube Insertion Attempts',\n",
       " 'Postoperative Complications',\n",
       " 'Intraoperative Complications',\n",
       " 'Wound infection',\n",
       " 'side effects of medication',\n",
       " 'rate of wound complications (wound dehiscence or infection)',\n",
       " 'time from surgery to starting adjuvant therapy among those with confirmed malignancies',\n",
       " 'Eckhard symptom scores',\n",
       " 'Eckhard symptom scores',\n",
       " 'Treatment success rates',\n",
       " 'Manometry data',\n",
       " 'Reflux score (clinical DeMeester score)',\n",
       " 'Reflux symptoms',\n",
       " 'pH metry',\n",
       " 'Adverse Events',\n",
       " 'Quality of Life index',\n",
       " 'EGD findings',\n",
       " 'CRP lab values',\n",
       " 'Hb lab values',\n",
       " 'Leucocyte lab values',\n",
       " 'number of days of hospitalisation',\n",
       " 'myotomy length',\n",
       " 'duration of procedure',\n",
       " 'Therapy failures',\n",
       " 'Retreatments',\n",
       " 'BCVA',\n",
       " 'Computerized Visual Field',\n",
       " 'Computerized Visual Field',\n",
       " 'VEP',\n",
       " 'RNFL',\n",
       " 'Liver function in plasma',\n",
       " 'kidney function in plasma',\n",
       " 'cardiovascular complications',\n",
       " 'diabetes mellitus',\n",
       " 'Determine in a randomised study if the response rate to docetaxel and oxaliplatin (ElTax) is comparable to epirubicin, oxaliplatin and capecitabine (EOX) and warrants further evaluation in advanced gastro-oesophageal cancer',\n",
       " 'In addition we will examine the effect of treatment on time to progression.',\n",
       " 'To examine the associated toxicity from treatment',\n",
       " 'To examine the effect of treatment on survival',\n",
       " 'To examine the effect of treatment on Quality of life.',\n",
       " 'Least Squares Mean Percent Change From Baseline To Month 12 in Lumbar Spine Areal Bone Mineral Density (BMD)',\n",
       " 'Number of Participants With Trough Serum Calcium Level Exceeding Predefined Limits At Least Once',\n",
       " 'Number of Participants With Trough Albumin-Corrected Calcium Level Exceeding Predefined Limits At Least Once',\n",
       " 'Number of Participants With Predefined Tier 1 Adverse Events',\n",
       " 'Least Squares Mean Percent Change From Baseline to Month 12 in Total Hip Areal BMD',\n",
       " 'Least Squares Mean Percent Change From Baseline to Month 12 in Femoral Neck Areal BMD',\n",
       " 'Least Squares Mean Percent Change From Baseline to Month 12 in Trochanter Areal BMD',\n",
       " 'Least Squares Mean Percent Change From Baseline to Month 12 in Total Body Areal BMD',\n",
       " 'Least Squares Mean Percent Change From Baseline to Month 12 in 1/3 Distal Forearm Areal BMD',\n",
       " 'Least Squares Mean Percent Change From Baseline to Month 12 in Trabecular Volumetric BMD (vBMD) of the Lumbar Spine',\n",
       " 'Least Squares Mean Percent Change From Baseline to Month 12 in Trabecular Volumetric BMD of the Hip',\n",
       " 'Least Squares Mean Percent Change From Baseline to Month 12 in Cortical Volumetric BMD of the Lumbar Spine',\n",
       " 'Least Squares Mean Percent Change From Baseline to Month 12 in Cortical Volumetric BMD of the Hip',\n",
       " 'Least Squares Mean Percent Change From Baseline to Month 12 in Urinary-N Telopeptides of Type 1 Collagen (u-NTx)',\n",
       " 'Least Squares Mean Percent Change From Baseline to Month 12 in Serum C-Terminal Propeptide of Type 1 Collagen (s-CTx)',\n",
       " 'Least Squares Mean Percent Change From Baseline to Month 12 in Serum N-Terminal Propeptide (s-P1NP)',\n",
       " 'Least Squares Mean Percent Change From Baseline to Month 12 in Serum Bone-Specific Alkaline Phosphatase (s-BSAP)',\n",
       " 'Least Squares Mean Percent Change From Baseline to Month 12 in Serum Osteocalcin',\n",
       " 'Bleb vascularity grading',\n",
       " 'Indiana Bleb Appearance Grading Scale (IBAGS)',\n",
       " 'Intra-ocular pressure',\n",
       " 'Indication for subconjunctival Mitomycin C injection or revision of surgery = yes / no',\n",
       " 'rate of treatment failure',\n",
       " 'rate of bacteria involved in microbiological failure',\n",
       " 'rate of clinical failure',\n",
       " 'to determine the maximum tolerated dose (MTD)',\n",
       " 'to evaluate the safety profile',\n",
       " 'Progression Free Survival (PFS)',\n",
       " 'Response rate (RR)',\n",
       " 'Overall survival (OS)',\n",
       " 'Relief of Post Traumatic Headache',\n",
       " 'Decrease in Pain',\n",
       " 'Demonstration of efficacy of cut-and-sew and stapler technique of appendage occlusion by intraoperative transesophageal echocardiography, central adjudication.',\n",
       " 'Demonstration of study feasibility, procedure safety, including rate of post-operative re-exploration for bleeding.',\n",
       " 'Overall survival (OS)',\n",
       " 'Cognitive failure-free survival (CFFS)',\n",
       " 'CFFS rate',\n",
       " 'Cumulative incidence of cognitive failure',\n",
       " 'OS in an \"as-treated\" analysis',\n",
       " 'Brain metastases-free survival (BMFS)',\n",
       " 'Incidence of adverse events',\n",
       " 'Maximum Tolerated Dose (MTD)',\n",
       " 'Number of Participants With Adverse Events (AEs)',\n",
       " 'vascular endothelial growth factor (VEGF) aqueous levels',\n",
       " 'pigment epithelium-derived factor (PEDF) aqueous levels',\n",
       " 'best-corrected visual acuity',\n",
       " 'central retinal thickness',\n",
       " 'Patient Controlled Analgesia (PCA) Hydromorphone Usage',\n",
       " 'Oral Analgesic Supplementation Use',\n",
       " 'Number of hidden lesions diagnosed in Arthroscopic Posteromedial Portal and not seen in classic arthroscopic portals and Intercondylar Portal.',\n",
       " 'Number of hidden lesions diagnosed during the arthroscopic procedure and not seen in preoperatively MRI.',\n",
       " 'Maximum Observed Plasma Concentration (Cmax)',\n",
       " 'Area Under the Plasma ConcentrationTime Curve From Time Zero to Last Quantifiable Time (AUC [0last])',\n",
       " 'Area Under the Plasma ConcentrationTime Curve From Time Zero to Infinite Time (AUC[0infinity])',\n",
       " 'Number of Participants with Adverse Events',\n",
       " 'Change in Percent Correct Score for the Treasure Hunt Task (THT)',\n",
       " 'Change in Percent Correct Score for the Mnemonic Similarity Test (MST)',\n",
       " 'Change in Depression, Anxiety, and Stress Scale (DASS)',\n",
       " 'Change in Intolerance of Uncertainty Scale (IUS)',\n",
       " 'Change in Baecke Physical Activity Questionnaire',\n",
       " 'Complete wound closure',\n",
       " 'Change in predicted medical expenditures between PriMatrix and Standard of Care',\n",
       " 'Change in quality of life measurements between PriMatrix and Standard of Care',\n",
       " 'Nonserious and serious adverse events',\n",
       " 'Unified Parkinson\\'s Disease Rating Scale (UPDRS) score: \"on\" medication, \"on\" stimulation',\n",
       " 'Unified Parkinson\\'s Disease Rating Scale (UPDRS) score: \"on\" medication, \"on\" stimulation',\n",
       " 'Unified Parkinson\\'s Disease Rating Scale, subscale III: Motor Evaluation (UPDRS-III) score: \"off\" medication, \"on\" stimulation',\n",
       " 'percentage of waking hours with good \"on\" time',\n",
       " \"Parkinson's Disease Questionnaire-39 (PDQ-39) patient satisfaction score\",\n",
       " 'ADHD Rating Scale - IV (ADHD-RS-IV)',\n",
       " 'Clinical Global Impressions - Improvement (CGI-I)',\n",
       " \"Children's Global Assessment Scale (C-GAS)\",\n",
       " 'Abnormal Involuntary Movement Scale (AIMS)',\n",
       " 'Barnes-Akathisia Rating Scale (BARS)',\n",
       " 'Simpson-Angus Scale (SAS)',\n",
       " \"Investigator's Global Assessment Scale\",\n",
       " 'Subject Self-Assessment',\n",
       " 'To determine what hemoglobin level is best for diabetic dialysis patients. Specific parameters: endothelial cell function and related expansile capacity of blood vessels. *Assessed through labs and pulse wave velocity test',\n",
       " 'Pulse rate, BP, respiratory rate, peripheral oxygen saturation, ECG during 6-min walk-test and Health Related Quality of Life Assessment as measured by questionnaires',\n",
       " 'Change in Gross Motor Function Measure Score',\n",
       " 'Change in GAITRite Mat Measures',\n",
       " 'Change in Nitrogen balance (NB)',\n",
       " 'Change in Nitrogen balance (NB)',\n",
       " 'Change in Nitrogen Balance',\n",
       " 'Composite outcome measure consisting of Lean body mass (LBM), and resting energy expenditure (REE).',\n",
       " 'Satiety scores',\n",
       " 'Adherence score to protein supplementation.',\n",
       " 'Safety and tolerability including blood test results, effects on the heart, pulse rate and blood pressure, and side effects.',\n",
       " 'Effects on the lung at 12 and 24hrs Effects on the heart, blood pressure and pulse rate at 8hrs Changes in the amount of glucose and potassium in the blood 4 and 8hrs Amount of drug in the body (blood and urine).',\n",
       " 'Postoperative SOFA score',\n",
       " 'Postoperative Kidney Disease Improving Global Outcome (KDIGO) class',\n",
       " '24-hour glucose levels',\n",
       " '24-hour insulin levels',\n",
       " '24-hour C-peptide levels',\n",
       " 'Hemoglobin A1C',\n",
       " 'Insulin sensitivity',\n",
       " 'Beta-cell responsivity index (a measure of beta-cell function)',\n",
       " 'Insulin secretion',\n",
       " 'Melatonin Amplitude',\n",
       " 'Cortisol Amplitude',\n",
       " 'Melatonin Phase',\n",
       " 'Cortisol Phase',\n",
       " 'Glycemic (\"Peripheral\") Rhythm Amplitude',\n",
       " 'Glycemic (\"Peripheral\") Rhythm Phase',\n",
       " 'To evaluate the pharmacokinetics (PK) of tazemetostat and its metabolite EPZ 6930, AUC0-t: area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration',\n",
       " 'To evaluate the pharmacokinetics (PK) of tazemetostat and its metabolite EPZ 6930, AUC0-: area under the plasma concentration-time curve from time 0 extrapolated to infinity',\n",
       " 'To evaluate the pharmacokinetics (PK) of tazemetostat and its metabolite EPZ 6930, AUC0-72: area under the plasma concentration-time curve from time 0 to 72 hours post dose',\n",
       " 'To evaluate the pharmacokinetics (PK) of tazemetostat and its metabolite EPZ 6930, Cmax: observed maximum plasma concentration',\n",
       " 'To evaluate the pharmacokinetics (PK) of tazemetostat and its metabolite EPZ 6930, Tmax: observed time at Cmax',\n",
       " 'To evaluate the pharmacokinetics (PK) of tazemetostat and its metabolite EPZ 6930, z: terminal phase elimination rate constant',\n",
       " 'To evaluate the pharmacokinetics (PK) of tazemetostat and its metabolite EPZ 6930, T 1/2: terminal elimination half-life',\n",
       " 'To evaluate the number of participants with treatment-emergent adverse events as assessed by CTCAE v5.0',\n",
       " 'To evaluate the number of abnormalities or changes in intensity of conditions noted during the physical exam',\n",
       " 'To evaluate change in blood pressure',\n",
       " 'To evaluate change in heart rate',\n",
       " 'To evaluate change in body temperature',\n",
       " 'To evaluate changes in concomitant medications',\n",
       " 'To evaluate change in electrical activity of the heartbeat, RR interval',\n",
       " 'To evaluate change in electrical activity of the heartbeat, PR interval',\n",
       " 'To evaluate change in electrical activity of the heartbeat, QRS complex',\n",
       " 'To evaluate change in electrical activity of the heartbeat, QT interval',\n",
       " 'To evaluate changes in clinical laboratory values, hematology',\n",
       " 'To evaluate changes in clinical laboratory values, serum chemistry',\n",
       " 'To evaluate changes in clinical laboratory values, urinalysis',\n",
       " 'To evaluate the safety of three escalating doses of DS003 (1 mg, 3 mg and 10 mg), administered in a vaginal tablet formulation, to healthy, HIV-negative female volunteers.',\n",
       " 'To assess the local (vaginal fluids) and systemic (plasma) DS003 PK profile and the 24 hour cervical tissue concentration when administered in three escalating doses of a vaginal tablet formulation.',\n",
       " 'Change From Baseline in Revised ALS Functional Rating Scale (ALSFRS-R) Score in Full Analysis Set (FAS) Population at 24 Weeks',\n",
       " 'Number of Participants With Death or a Specified State of Disease Progression',\n",
       " 'Change From Baseline in % Forced Vital Capacity (%FVC) in Full Analysis Set (FAS) Population at 24 Weeks',\n",
       " 'Percentage of Participants With Adverse Events',\n",
       " 'Percentage of Participants With Adverse Drug Reactions',\n",
       " 'Percentage of Participants With Laboratory Tests for Which the Incidence of Abnormal Changes Was 5% or Higher in Either Group',\n",
       " 'Percentage of Participants With Abnormal Changes in Sensory Examinations',\n",
       " 'Change From Baseline to Week 8 in Weekly Mean of the Average Daily (24-hour) Pain Intensity Score for FX006 60 mg vs TCA IR 40 mg',\n",
       " 'Change From Baseline to Week 10 in Weekly Mean of the Average Daily (24-hour) Pain Intensity Score for FX006 60 mg vs TCA IR 40 mg',\n",
       " 'Change From Baseline to Week 12 in Weekly Mean of the Average Daily (24-hour) Pain Intensity Score for FX006 60 mg vs TCA IR 40 mg',\n",
       " 'Change From Baseline to Each of Weeks 8, 10, and 12 in Weekly Mean of the Average Daily (24-hour) Pain Intensity Score for FX006 10mg and 40 mg vs TCA IR 40 mg',\n",
       " 'Change From Baseline to Each of Weeks 1, 2, 3, 4, 5, 6, 7, 9, and 11 in Weekly Mean of the Average Daily (24-hour) Pain Intensity Score.',\n",
       " 'WOMAC A (Pain Subscale) Change From Baseline at Week 8',\n",
       " 'WOMAC A1 (Pain on Walking Question) Change From Baseline at Week 8',\n",
       " 'WOMAC B (Stiffness Subscale) Change From Baseline at Week 8',\n",
       " 'WOMAC C (Function Subscale) Change From Baseline at Week 8',\n",
       " 'Percent of Responders According to OMERACT-OARSI Criteria at Week 8',\n",
       " 'Responder Status as Defined by the Proportion of Patients Achieving >50% Improvement From Baseline in the Mean Daily Pain Intensity Scores at Week 8',\n",
       " 'Responder Status as Defined by the Proportion of Patients Achieving >30% Improvement From Baseline in the Mean Daily Pain Intensity Scores at Week 8',\n",
       " 'Responder Status as Defined by the Proportion of Patients Achieving >20% Improvement From Baseline in the Mean Daily Pain Intensity Scores at Week 8',\n",
       " 'Patient Global Impression of Change Scores at Week 8',\n",
       " 'Clinical Global Impression of Change Scores at Week 8',\n",
       " 'Average Weekly and Total Consumption of Rescue Medications Over 8 Weeks.',\n",
       " 'Change in handover quality',\n",
       " 'Handover length',\n",
       " 'Missed care / procedures / diagnostic tests',\n",
       " 'Patients satisfaction',\n",
       " 'Live Birth Rate Per Started Cycle and Live Birth From Cryopreserved Embryos Originating From, and Occurring Within 6 Months of the Initial Treatment Cycle Will be Included in the Total Live Birth Rate Per Started Cycle.',\n",
       " 'Cumulative Ongoing Pregnancy Rate',\n",
       " 'Change in Weight',\n",
       " 'Change Waist Circumference',\n",
       " 'Change in Self-Reported Physical Activity',\n",
       " 'Change in Self-Reported Sleep Quantity',\n",
       " 'Change in Self-Reported Daily Caloric Consumption',\n",
       " 'Baseline Positive and Negative Symptoms of Schizophrenia (PANSS) Total Score',\n",
       " 'The Change From Baseline to Week 6 or the Last Post-randomization Assessment During Double-blind Treatment in the Positive and Negative Symptoms of Schizophrenia (PANSS) Total Score.',\n",
       " 'Number of Participants With Response',\n",
       " 'Change in Positive and Negative Symptoms of Schizophrenia (PANSS) Positive Subscale Score',\n",
       " 'Change in Positive and Negative Symptoms of Schizophrenia (PANSS) Negative Subscale Score',\n",
       " 'Change in Positive and Negative Symptoms of Schizophrenia (PANSS) General Psychopathology Subscale Score',\n",
       " 'Positive and Negative Symptoms of Schizophrenia (PANSS) Positive Factor Score',\n",
       " 'Change in Positive and Negative Symptoms of Schizophrenia (PANSS) Negative Factor Score',\n",
       " 'Change in Positive and Negative Symptoms of Schizophrenia (PANSS) Disorganized Thought Factor Score',\n",
       " 'Change in Positive and Negative Symptoms of Schizophrenia (PANSS) Uncontrolled Hostility/Excitement Factor Score',\n",
       " 'Change in Positive and Negative Symptoms of Schizophrenia (PANSS) Anxiety/Depression Factor Score',\n",
       " 'Clinical Global Impression (CGI-S) - Severity for Schizoaffective Disorder Score at Baseline',\n",
       " 'Change in Clinical Global Impression (CGI-S) - Severity for Schizoaffective Disorder',\n",
       " 'Clinical Global Impression (CGI-C) - Change for Schizoaffective Disorder',\n",
       " 'Optimally Tolerated Dose',\n",
       " 'Toxicity Profile',\n",
       " 'Proportion of patients diagnosed with angina pectoris secondary to coronary heart disease',\n",
       " 'Symptoms',\n",
       " 'Diagnosis',\n",
       " 'Investigations',\n",
       " 'Treatment',\n",
       " 'Long-term outcome',\n",
       " 'Percentage of Participants With at Least One Clinical Adverse Experience',\n",
       " 'Percentage of Participants Who Discontinued Study Treatment Due to a Clinical Adverse Experience',\n",
       " 'Percentage of Participants With at Least One Laboratory Adverse Experience',\n",
       " 'Percentage of Participants Who Discontinued Study Treatment Due to a Laboratory Adverse Experience',\n",
       " 'Change From Baseline in Cluster of Differentiation 4 (CD4) Cell Count',\n",
       " 'Change From Baseline in CD4 Cell Percentage',\n",
       " 'Percentage of Participants Achieving >=1 log10 Reduction From Baseline in Human Immunodeficiency Virus (HIV) Ribonucleic Acid (RNA) or Had an HIV RNA Assessment of <200 Copies/mL',\n",
       " 'Percentage of Participants Achieving HIV RNA <40 Copies/mL',\n",
       " 'Percentage of Participants Achieving HIV RNA <200 Copies/mL',\n",
       " \"Decrease of cytokines concentration TARC, IL-6, IL1-RA, sCD30, TNFR1) as markers of response during treatment and during early follow-up in Hodgkin's disease\",\n",
       " 'Correlation between the decrease of cytokines plasma levels and event-free survival',\n",
       " 'Feasibility of study intervention measured by recruitment rate',\n",
       " 'Feasibility of study intervention measured by accrual rate',\n",
       " 'Feasibility of study intervention measured by adherence to intervention',\n",
       " 'Feasibility of study intervention measured by retention',\n",
       " 'Longitudinal changes in the Generalized Anxiety Disorder-7 (GAD-7) score for anxiety',\n",
       " 'Longitudinal changes in the Patient Health Questionnaire (PHQ-9) score for depression',\n",
       " 'Combined analysis of PHQ-9 and GAD-7',\n",
       " 'Longitudinal changes in the Insomnia Severity Index (ISI)',\n",
       " 'Longitudinal changes in the PROMIS Fatigue Scale',\n",
       " 'Longitudinal changes in the Fear of Recurrence Inventory Severity Subscale',\n",
       " 'Longitudinal changes in the Health Status Questionnaire (SF-36)',\n",
       " 'Determine costs associated with stepped care mental health and enhanced usual care',\n",
       " 'Analysis of differential effects of intervention measured by subgroup stratification',\n",
       " 'Longitudinal changes in the Impact of Events Scale-Revised (IES-R)',\n",
       " 'Observation of acute kidney injury',\n",
       " 'Organ failure during first 48 hours and during stay on intensive care unit',\n",
       " 'Duration of stay on intensive care unit and in hospital',\n",
       " 'Mortality during stay on intensive care unit',\n",
       " 'The Change From Baseline to 6-week Scores for The Total Tic Subscale (TTS)',\n",
       " 'The Change From Baseline to 6-week Scores for the Yale Global Tic Severity Scale (YGTSS) Total Score.',\n",
       " 'The Change From Baseline to 6-week Score for the Clinical Global Impression -Improvement (CGI-I).',\n",
       " 'The Change From Baseline to 6-week Score for the Patient Global Impression of Improvement (PGI-I).',\n",
       " \"Changes in the Children's Yale-Brown Obsessive-Compulsive Scale (CY-BOCS) From Baseline to 6-weeks.\",\n",
       " 'The Change From Baseline to 6-week in Plasma Amino Acid Levels',\n",
       " 'The Change From Baseline to 6-week in Scores of the DuPaul Attention Deficit Hyperactivity Disorder Rating Scale.',\n",
       " 'The Change From Baseline to 6-week in Scores of the Child Depression Inventory - Short Version (CDI-S) Scale',\n",
       " 'The Change From Baseline to 6-week in Scores of the Multi-Dimensional Anxiety Scale for Children (MASC)',\n",
       " 'Expanded Pittsburgh Side Effect Scale Modified to Include Side Effects of Riluzole and D-serine.',\n",
       " 'Expanded Pittsburgh Side Effect Scale Modified to Include Side Effects of Riluzole and D-serine.',\n",
       " 'Expanded Pittsburgh Side Effect Scale Modified to Include Side Effects of Riluzole and D-serine.',\n",
       " 'Expanded Pittsburgh Side Effect Scale Modified to Include Side Effects of Riluzole and D-serine.',\n",
       " 'Expanded Pittsburgh Side Effect Scale Modified to Include Side Effects of Riluzole and D-serine.',\n",
       " 'Rate of radiation dermatitis grade 2',\n",
       " 'Rate of radiation dermatitis grade 2',\n",
       " 'Rate of radiation dermatitis grade 3',\n",
       " 'Pain score',\n",
       " 'Rate of radiation-induced oral mucositis grade 2',\n",
       " 'Rate of radiation-induced oral mucositis grade 3',\n",
       " 'Fecal cholesterol excretion',\n",
       " 'intestinal cholesterol absorption',\n",
       " 'Change in adaptive coping strategies',\n",
       " 'Change in maladaptive coping strategies',\n",
       " 'Change in Continuous Adherence',\n",
       " 'Change in continuous adherence',\n",
       " 'Change in Demographic data',\n",
       " 'Goal setting tool',\n",
       " 'Changes in 24-hour dietary intake recall',\n",
       " 'Changes in 3-day dietary intake record',\n",
       " 'Changes in 24-hour physical activity recall',\n",
       " 'Changes in 3-day physical activity record',\n",
       " 'Changes in Anthropometric measurements',\n",
       " 'Changes in Social Cognitive Theory (SCT) variables',\n",
       " 'Changes in blood pressure (BP) measurements',\n",
       " 'Process measure questionnaire',\n",
       " 'Education measures',\n",
       " 'Extension measures',\n",
       " 'Plasma levels of study drugs will be taken on Day 1 & 8.',\n",
       " 'Safety is evaluated by: -AEs monitored at each visit',\n",
       " '-Physical exam, vital signs, & ECOG performance status score',\n",
       " '-ECG',\n",
       " '-Serum Pepsinogen levels monitored',\n",
       " 'Terminal half-life (t1/2, as data permit), AUC(0-t), volume of distribution at steady state (Vdss), and clearance (Cl) of docetaxel',\n",
       " 'Lowest measured absolute neutrophil count.',\n",
       " 'Physical exam findings, blood pressure, heart rate, clinical laboratory tests, clinical monitoring/observation, and adverse events reporting.',\n",
       " \"Determine if the substitution of raltegravir for 2 NRTI's in patients with evidence of peripheral lipoatrophy and who have sustained HIV virological suppression will result in evidence of an increased in volume of peripheral fat within one year.\",\n",
       " 'Determining whether the patients will continue to have sustained virological suppression upon switching to a raltegravir-based regimen.',\n",
       " 'Determining what, if any, adverse effects the patients may develop..',\n",
       " 'Extended high frequency audiometry',\n",
       " 'Transient Evoked Otoacoustic Emission',\n",
       " 'technical success',\n",
       " 'clinical success',\n",
       " 'adverse events',\n",
       " 're-interventions',\n",
       " 'overall survival',\n",
       " 'Number of Participants Who Achieved 4*10^6 CD34+ Cells/kg',\n",
       " 'Participant Counts of Summarized Adverse Events (AE) During Treatment',\n",
       " 'Number of Transplantations That Achieved Polymorphonuclear Leukocyte (PMN) Engraftment Grouped by Days to Engraftment',\n",
       " 'Number of Transplantations That Achieved Platelet (PLT) Engraftment Grouped by Days to Engraftment',\n",
       " 'Number of Participants With a Durable Graft at 12 Months Post Transplantation',\n",
       " 'Growth',\n",
       " 'Growth',\n",
       " 'Stool patterns (3-day GI symptom and behavior diary - stool frequency and stool consistency)',\n",
       " 'GI tolerance (3-day GI symptom and behavior diary - including GI symptoms, GI-related behaviors, and milk intake)',\n",
       " 'Fecal microbiota composition and diversity (16S rRNA sequencing and qPCR)',\n",
       " 'Fecal markers (pH, fecal organic acids, and protein markers of gut health)',\n",
       " 'Gene expression (infant exfoliated and microbial cell gene expression by shotgun sequencing)',\n",
       " 'Adverse events / Morbidity',\n",
       " 'Iron status',\n",
       " 'Growth',\n",
       " 'Tolerance (gastrointestinal)',\n",
       " 'Efficacy of SPN-812 assessed by Swanson, Kotkin, Agler, M-Flynn, and Pelham Scale- Combined Score (SKAMP-CS)',\n",
       " 'Effect of SPN-812 assessed longitudinally by SKAMP-CS',\n",
       " 'Effect of SPN-812 assessed longitudinally by Permanent Product (PERMP) math test',\n",
       " 'Effect of SPN-812 on Clinical Global Impression-Severity (CGI-S) scale',\n",
       " 'Effect of SPN-812 on SKAMP Attention and SKAMP Deportment subscales',\n",
       " 'Effect of SPN-812 assessed longitudinally on SKAMP Attention and SKAMP Deportment subscales',\n",
       " 'Effect of SPN-812 assessed by ADHD Rating Scale-5 (ADHD-RS-5) Total Score and subscales',\n",
       " 'Effect of SPN-812 assessed by Clinical Global Impression-Improvement (CGI-I) scale',\n",
       " 'Effect of SPN-812 assessed by categorical CGI-I Responder Rate',\n",
       " 'Effect of SPN-812 assessed by 50% Responder Rate to ADHD Rating Scale-5 baseline',\n",
       " 'Effect of SPN-812 assessed by Conners 3rd Edition-Parent Report Short Form (Conners 3-PS) Composite T score',\n",
       " 'Time to recurrence',\n",
       " 'Disease-free Survival',\n",
       " 'Disease-free Specific Survival',\n",
       " 'Overall Survival',\n",
       " 'Association between HRV and renal function (eGFR and UACR)',\n",
       " 'Clinical characteristics of patients',\n",
       " 'Percentage of Subjects Without Symptoms of Atrial Fibrillation at 3 Months',\n",
       " 'Percentage of Subjects Without Atrial Arrhythmia at 3 Months',\n",
       " 'Change in Mean C-Reactive Protein Level',\n",
       " 'Change in Mean Quality of Life Score',\n",
       " 'Change in Lipid Levels',\n",
       " 'Maximal oxygen consumption (VO2max)',\n",
       " 'Maximal power output (Pmax)',\n",
       " 'Exhaled NO (eNO)',\n",
       " 'Heart rate variability',\n",
       " 'Force Expiratory Volume in one second (FEV1)',\n",
       " 'HAM-D total score',\n",
       " 'Time to relapse',\n",
       " 'Body Dysmorphic Disorder Symptoms (as measured by the BDD-YBOCS)',\n",
       " 'Insight regarding BDD Symptoms (as measured by the BABS)',\n",
       " 'Depressive symptoms (as measured by the BDI-II)',\n",
       " 'Functioning and life satisfaction (as measured by the SDS and Q-LESQ-SF)',\n",
       " 'Treatment credibility and satisfaction with treatment (as measured by the Credibility/Expectancy Rating and CSQ-8)',\n",
       " 'Beliefs about appearance (as measured by the ASI-R)',\n",
       " 'Neuropsychological functioning (as measured by the ROCF)',\n",
       " 'Information processing (as measured by the ERT)',\n",
       " 'walking distance without pain (in meters)',\n",
       " 'maximal oxygen consumption (VO2peak in ml.min)',\n",
       " 'Number of Subjects With Any Solicited Local or General Symptoms',\n",
       " 'Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)',\n",
       " 'Number of Subjects With Serious Adverse Events (SAEs)',\n",
       " 'Number of Subjects With Any Solicited Local or General Symptoms',\n",
       " 'Number of Subjects With Any, Grade 3 and Related Unsolicited AEs',\n",
       " 'Number of Subjects With Serious Adverse Events (SAEs)',\n",
       " 'Predischarge distribution of frailty syndrome according to Fried phenotype frailty scale',\n",
       " 'Predischarge distribution of frailty syndrome according to instrumental activities of daily living scale',\n",
       " 'Results of interventional treatment',\n",
       " 'Incidence of periprocedural infarction',\n",
       " 'Incidence of contrast induced nephropathy',\n",
       " 'Incidence of bleeding',\n",
       " 'Major cardiovascular events',\n",
       " 'Major cardiovascular events',\n",
       " 'Major cardiovascular events',\n",
       " 'Major cardiovascular events',\n",
       " 'Major cardiovascular events',\n",
       " 'Major cardiovascular events',\n",
       " 'Major cardiovascular events',\n",
       " '3 years relapse-free survival',\n",
       " '5 years overall survival',\n",
       " 'Mean Area-under-the-Curve (AUC) Analysis of Change From Baseline in Pupil Diameter (mm) During Surgery',\n",
       " 'Mean Area-under-the-Curve Analysis of Ocular Pain Visual Analog Scale (VAS) Score Within 12 Hours Postoperatively',\n",
       " 'Photophobia at 6 Hours After Surgery (Ocular Pain and Symptoms Numerical Ordinal Scale [Numerical Rating System - NRS] Scores)',\n",
       " 'Photophobia at Day 1 After Surgery (Ocular Pain and Symptoms Numerical Ordinal Scale [Numerical Rating System - NRS] Scores)',\n",
       " 'Best Corrected Visual Acuity (BVCA) Log Score on Day 1',\n",
       " 'Ocular Inflammation in Summed Ocular Inflammation Score (SOIS) Grade on Day 1',\n",
       " 'Ocular Pain VAS Score After Day of Surgery - Day 1',\n",
       " 'Number of volunteers with adverse events',\n",
       " 'To determine the pharmacokinetic profile of CHR-5154 and its metabolite CHR-5426.',\n",
       " 'To compare the pharmacokinetic profile of CHR-5154 and CHR-5426 after a single dose of CHR-5154 in the fed and fasted state.',\n",
       " 'Incidence of adverse events as assessed by the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) version 5',\n",
       " 'Progression-free survival assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria and immune related (ir)RECIST',\n",
       " 'Overall survival assessed by RECIST 1.1 criteria and irRECIST',\n",
       " 'Overall response rate assessed by RECIST 1.1 criteria and irRECIST',\n",
       " 'Change in weight - weight loss',\n",
       " 'Metabolic control',\n",
       " 'Metabolic control',\n",
       " 'Metabolic control',\n",
       " 'Adherence to Mediterranean Diet',\n",
       " 'Reduction of bladder pain visual analog scale (VAS)',\n",
       " 'Interstitial cystitis symptom index (ICSI)',\n",
       " 'Functional bladder capacity',\n",
       " 'Maximum flow rate (Qmax)',\n",
       " 'Voided volume',\n",
       " 'Postvoid residual volume',\n",
       " 'Interstitial cystitis problem index (ICPI)',\n",
       " 'Symptom Rating Test',\n",
       " 'Coping Questionnaire',\n",
       " 'Family Member Impact Questionnaire',\n",
       " 'Alcohol, Drugs and the Family Social Support Scale',\n",
       " 'Maximum observed plasma concentration (Cmax)',\n",
       " 'Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration [AUC(0-T)]',\n",
       " 'Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)]',\n",
       " 'Incidence of nonserious adverse events (AE), serious adverse events (SAE), and AE leading to discontinuation',\n",
       " 'Number of clinically significant changes in clinical laboratory values, vital signs, ECGs, and physical examinations',\n",
       " 'Time to resolution of all clinical symptoms of influenza as reported by the subjects',\n",
       " 'Time to resolution of each individual symptom of influenza',\n",
       " 'Change of values obtained by ultrasonography optic nerve sheath measurement from baseline to 2 hours post starting infusion of nicardipine or labetalol.',\n",
       " 'variation of diastolic and systolic velocities in middle cerebral artery before and after administration of either labetalol or nicardipine by i.v. route',\n",
       " 'variation of PI in middle cerebral artery before and after administration of either labetalol or nicardipine by i.v. route',\n",
       " 'proportion of pathologic PI in middle cerebral artery in each group',\n",
       " 'proportion of optic nerve sheath up to 5.8 mm in each group',\n",
       " 'values of optic nerve sheath diameter in each group',\n",
       " 'renal function, uric acid, electrolytes, adverse events and mortality in pre-phase and the two following cycles of chemotherapy, time and dose compliance of chemotherapy',\n",
       " 'response rate, incidence of tumor lysis syndrome',\n",
       " 'Change in Knee extensor isokinetic muscle fatigability index at 12 weeks',\n",
       " 'Change in Muscle blood flow at 12 weeks',\n",
       " 'Change in Isokinetic and isometric peak knee extension force at 12 weeks',\n",
       " 'Change in Short Physical Performance Battery at 12 weeks',\n",
       " 'Change in Timed Up-and-Go at 12 weeks',\n",
       " 'Change in Lean Body Mass, as estimated by diagnostic ultrasound at 12 weeks',\n",
       " 'Change in myosteatosis, as estimated by diagnostic ultrasound at 12 weeks',\n",
       " 'Change in Grip strength at 12 weeks',\n",
       " 'Change in Activities-Specific Balance Confidence (ABC) Scale at 12 weeks',\n",
       " 'Change in Short Form Health Survey (SF-36) Scale at 12 weeks',\n",
       " 'Change in Falls Efficacy Scale (FES) at 12 weeks',\n",
       " 'Change in weight at 12 weeks',\n",
       " 'Change in height at 12 weeks',\n",
       " 'Change in body water at 12 weeks',\n",
       " 'Change in Blood Pressure at 12 weeks',\n",
       " 'Rate of instrumental delivery',\n",
       " 'Adequate analgesia',\n",
       " 'Total amount of local anesthetic',\n",
       " 'Time-related amount of local anesthetic',\n",
       " 'Motor block episodes',\n",
       " 'Anesthesiologist working time',\n",
       " 'Health economic assessment',\n",
       " 'The incidence of overall Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events (AEs) leading to discontinuation',\n",
       " 'Absolute values from double-blind (DB) Baseline of Study SEP361-201 and open-label (OL) Baseline of Study SEP361-202 in clinical laboratory tests (hematology)',\n",
       " 'Changes from double-blind (DB) Baseline of Study SEP361-201 and open-label (OL) Baseline of Study SEP361 202 in clinical laboratory tests (hematology)',\n",
       " 'Changes from double-blind (DB) Baseline of Study SEP361-201 and open-label (OL) Baseline of Study SEP361-202 in clinical laboratory tests (serum chemistry)',\n",
       " 'Absolute values from double-blind (DB) Baseline of Study SEP361-201 and open-label (OL) Baseline of Study SEP361-202 in clinical laboratory tests (serum chemistry)',\n",
       " 'Changes from double-blind (DB) Baseline of Study SEP361-201 and open-label (OL) Baseline of Study SEP361-202 in clinical laboratory tests (urinalysis)',\n",
       " 'Absolute values from double-blind (DB) Baseline of Study SEP361-201 and open-label (OL) Baseline of Study SEP361-202 in clinical laboratory tests (urinalysis)',\n",
       " 'Changes from double-blind (DB) Baseline of Study SEP361-201 and open-label (OL) Baseline of Study SEP361-202 in clinical laboratory tests (glucose and lipid panel)',\n",
       " 'Absolute values from double-blind (DB) Baseline of Study SEP361-201 and open-label (OL) Baseline of Study SEP361 202 in clinical laboratory tests (glucose and lipid panel)',\n",
       " 'Changes from double-blind (DB) Baseline of Study SEP361-201 and open-label (OL) Baseline of Study SEP361-202 in clinical laboratory tests (prolactin)',\n",
       " 'Absolute values from double-blind (DB) Baseline of Study SEP361-201 and open-label (OL) Baseline of Study SEP361-202 in clinical laboratory tests (prolactin)',\n",
       " 'Changes from double-blind (DB) Baseline of Study SEP361-201 and open-label (OL) Baseline of Study SEP361-202 in clinical laboratory tests (glycosylated hemoglobin (HbA1c))',\n",
       " 'Absolute values from double-blind (DB) Baseline of Study SEP361-201 and open-label (OL) Baseline of Study SEP361-202 in clinical laboratory tests (glycosylated hemoglobin (HbA1c))',\n",
       " 'Changes from DB Baseline of Study SEP361-201 and OL Baseline of Study SEP361-202 in clinical evaluations (vital signs)',\n",
       " 'Absolute values from DB Baseline of Study SEP361-201 and OL Baseline of Study SEP361-202 in clinical evaluations (vital signs)',\n",
       " 'Changes from DB Baseline of Study SEP361-201 and OL Baseline of Study SEP361-202 in clinical evaluations (body weight)',\n",
       " 'Absolute values from DB Baseline of Study SEP361-201 and OL Baseline of Study SEP361-202 in clinical evaluations (body weight)',\n",
       " 'Changes from DB Baseline of Study SEP361-201 and OL Baseline of Study SEP361-202 in clinical evaluations (BMI)',\n",
       " 'Absolute values from DB Baseline of Study SEP361-201 and OL Baseline of Study SEP361-202 in clinical evaluations (BMI)',\n",
       " 'Changes from DB Baseline of Study SEP361-201 and OL Baseline of Study SEP361-202 in clinical evaluations (blood pressure [supine and standing]).',\n",
       " 'Absolute values from DB Baseline of Study SEP361-201 and OL Baseline of Study SEP361-202 in clinical evaluations (blood pressure [supine and standing]).',\n",
       " 'Changes from DB Baseline of Study SEP361-201 and OL Baseline of Study SEP361-202 in clinical evaluations (heart rate [supine and standing])',\n",
       " 'Absolute values from DB Baseline of Study SEP361-201 and OL Baseline of Study SEP361-202 in clinical evaluations (heart rate [supine and standing])',\n",
       " 'Changes from DB Baseline of Study SEP361-201 and OL Baseline of Study SEP361-202 in clinical evaluations (12 lead ECGs)',\n",
       " 'Absolute values from DB Baseline of Study SEP361-201 and OL Baseline of Study SEP361-202 in clinical evaluations (12 lead ECGs)',\n",
       " 'Severity of suicidal ideation and suicidal behavior using the C-SSRS',\n",
       " 'Frequency of suicidal ideation and suicidal behavior using the Columbia - Suicide Severity Rating Scale (C-SSRS)',\n",
       " 'time to relapse during the 26 week OL period for subjects who demonstrated a clinical response to 4 weeks of treatment with SEP-363856.',\n",
       " 'Rate of relapse during the 26 week OL period for subjects who demonstrated a clinical response to 4 weeks of treatment with SEP-363856.',\n",
       " 'Changes from DB Baseline of Study SEP361-201 and OL Baseline of Study SEP361-202 in Positive and negative syndrome scale (PANSS) total score and subscale scores (positive, negative, and general psychopathology)',\n",
       " 'Change from DB Baseline of Study SEP361-201 and OL Baseline of Study SEP361-202 in Clinical global impression - severity (CGI-S) score.',\n",
       " 'Change from DB Baseline of Study SEP361-201 and OL Baseline of Study SEP361 202 in Brief Negative Symptom Scale (BNSS) total score.',\n",
       " 'Change from DB Baseline of Study SEP361-201 and OL Baseline of Study SEP361-202 in Montgomery-Asberg Depression Rating Scale (MADRS) total score.',\n",
       " 'Proportion of subjects who achieve a response, defined as a 20% or greater improvement in PANSS total score from the baseline',\n",
       " 'We expect to see increased urinary 8-isoprostane in acute pediatric asthmatics',\n",
       " 'We expect urinary 8-isoprostane levels to be higher with increased pediatric asthma severity.',\n",
       " 'Change in serum phosphorus',\n",
       " 'Change in serum phosphorus level by time',\n",
       " 'Percent of patients meeting the target range of serum phosphorus (3.5-6.0 mg/dL) and achieving time',\n",
       " 'Change in corrected serum Ca level',\n",
       " 'Change in CaP',\n",
       " 'Change in intact PTH',\n",
       " 'Malaria Case Incidence',\n",
       " 'Malaria Infection prevalence',\n",
       " 'Entomological Inoculation Rate',\n",
       " 'Transplant-related mortality at 180 days',\n",
       " 'Disease response (complete response)',\n",
       " 'Progression-free survival',\n",
       " 'Overall survival at 1 year',\n",
       " \"Percentage of subjects rated a treatment success based on the Investigator's Global Assessment (IGA)\",\n",
       " 'Percentage of subjects rated a treatment success for each of the clinical signs of psoriasis (scaling, erythema and plaque elevation)',\n",
       " 'Change from Baseline in pruritus score',\n",
       " 'IGA \"treatment success\" at Day 15',\n",
       " 'Effect of an intensive cognitive rehabilitation program in neuropsychological performance of a population of patients with multiple sclerosis or clinical isolated syndrome.',\n",
       " 'Neuropsychological profile of a population of patients with multiple sclerosis or clinical isolated syndrome.',\n",
       " 'Percentage of patients with Cognitive Dysfunction',\n",
       " 'Relation between Expended Disability Status Scale score and cognitive dysfunction.',\n",
       " 'Impact of depression on neuropsychological performance.',\n",
       " 'Relation between cognitive dysfunction and the 9-hole peg test.',\n",
       " 'Relation between cognitive dysfunction and the 25-foot walk test.',\n",
       " 'partial response (PR)',\n",
       " 'complete response (CR)',\n",
       " 'Median time to progression (TTP)',\n",
       " 'overall survival (OS)',\n",
       " 'Transplant-related mortality (TRM)',\n",
       " 'Incidence of engraftment',\n",
       " 'Evaluation of overall (OS) and disease-free survival (DFS)',\n",
       " 'Cumulative incidence of relapse, death from disease, and non-relapse mortality (NRM)',\n",
       " 'Cumulative incidences and severity of acute and chronic Graft-versus-Host disease',\n",
       " 'Immune Recovery (to be determined in a subgroup of patients)',\n",
       " 'Shoulder disability',\n",
       " 'Patient satisfaction',\n",
       " 'Quality of life',\n",
       " 'Pain with rest, normal activities, and strenuous activities',\n",
       " 'Patient perceived global rating of effect',\n",
       " 'Additional healthcare utilization and medication use',\n",
       " 'Patient Function Response to Biologic Therapy as measured by RAPID3',\n",
       " 'Patient Function Response to Biologic Therapy as measured by HAQ-DI',\n",
       " 'Patient Quality of Life Response to Biologic Therapy as measured by PROMIS10',\n",
       " 'Patient Quality of Life Response to Biologic Therapy as measured by PSAID',\n",
       " 'Physician assessment of disease response to biologic therapy as measured by swollen joint count.',\n",
       " 'Physician assessment of disease response to biologic therapy as measured by tender joint count.',\n",
       " 'Disease Activity and Response to Biologic Therapy as measured by Patient Pain Assessment',\n",
       " 'Disease Activity and Response to Biologic Therapy as measured by Physician Global Assessment',\n",
       " 'Disease Activity and Response to Biologic Therapy as measured by Patient Global Assessment',\n",
       " 'DESCRIPTIVE: timing endpoints: hours after presentation before any observed intervention',\n",
       " 'hospital length of stay',\n",
       " 'disposition after emergency care',\n",
       " 'DESCRIPTIVE: blood products utilization: # units',\n",
       " 'DESCRIPTIVE: reversal products given (with doses and timing)',\n",
       " 'DESCRIPTIVE: in-hospital complications: incidence, description',\n",
       " 'DESCRIPTIVE: costs of treatment',\n",
       " 'Disease Control Rate (DCR)',\n",
       " 'Progression Free Survival (PFS)',\n",
       " 'Overall Survival (OS)',\n",
       " 'Number and type of adverse events',\n",
       " 'To determine the Maximum Tolerated Dose (MTD) of MM-398 in combination with intravenous cyclophosphamide by assessing the occurrence of dose limiting toxicities',\n",
       " 'Measurement of plasma levels of study drug to determine the pharmacokinetic properties of MM-398 in combination with cyclophosphamide',\n",
       " 'Progression free survival (PFS)',\n",
       " 'Overall survival (OS)',\n",
       " 'Radiological response rate (in patients with measurable disease)',\n",
       " 'Duration of response',\n",
       " 'Cancer-Antigen 125 (CA-125) response rate per GCIG (Gynaecologic Cancer Intergroup) and change in CA-125',\n",
       " 'Toxicity profile',\n",
       " 'Patient Reported Outcome: Physical well-being',\n",
       " 'Patient Reported Outcome: Social/family well-being',\n",
       " 'Patient Reported Outcome: Functional well being',\n",
       " 'Patient Reported Outcome: Emotional well being',\n",
       " 'Change in selected biomarkers in induced sputum',\n",
       " 'Change in selected biomarkers in peripheral blood',\n",
       " 'Change in selected biomarkers in induced sputum',\n",
       " 'Change in selected biomarkers in exhaled breath condensate',\n",
       " 'Change in selected biomarkers in induced sputum',\n",
       " 'Change in selected biomarkers in exhaled breath condensate',\n",
       " 'Change in selected biomarkers in induced sputum',\n",
       " 'Change in selected biomarkers in exhaled breath condensate',\n",
       " 'Change in selected biomarkers in peripheral blood',\n",
       " 'Gait speed',\n",
       " 'Swing duration',\n",
       " 'Stance duration',\n",
       " 'Cadence',\n",
       " 'Stride length',\n",
       " 'Clinical response as measured by a reduction in the CDAI total score',\n",
       " 'CDAI reduction by number of points and difference from baseline',\n",
       " 'proportion of subjects showing a clinical remission by measure of CDAI score',\n",
       " 'The change in total CDAI score',\n",
       " 'The change in IBDQ total score and category sub-scores',\n",
       " 'The change in CRP level',\n",
       " 'The change in fecal calprotectin levels',\n",
       " 'Change in TETRAS spiral rating after stimulation',\n",
       " 'Change in TETRAS spiral rating during stimulation',\n",
       " 'Self-report improvement',\n",
       " 'Pain pressure thresholds (PPTs)',\n",
       " 'Lingual muscle endurance',\n",
       " 'Maximal mouth opening (MMO)',\n",
       " 'Lingual extensibility',\n",
       " 'Ability to generate mental motor images',\n",
       " 'Change in Uncorrected Distance Visual Acuity',\n",
       " 'Change in Subjective Refraction',\n",
       " 'Change in keratometry',\n",
       " 'Change in Higher Order Aberrations',\n",
       " 'Change in pachymetry',\n",
       " 'Subjective questionnaire score',\n",
       " 'Change in Corrected Distance Visual Acuity',\n",
       " 'Change in Spherical aberration',\n",
       " 'Event-Free survival',\n",
       " 'Time to Event (events: local recurrence, regional recurrence, local-regional recurrence or progression, distant recurrence, or death from any cause)',\n",
       " 'Time to recurrence (events: local recurrence, regional recurrence, local-regional recurrence or progression, distant recurrence)',\n",
       " 'Toxicity',\n",
       " 'Response Assessment',\n",
       " 'Count of Participants With SS1P Antibody Formation',\n",
       " 'Count of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0) Who Were Administered SS1P and Pentostatin or Cyclophosphamide',\n",
       " 'Recommended Phase 2 Dose (RP2D) in Drug Lot FIL129J01',\n",
       " 'Overall Survival',\n",
       " 'Progression-free Survival',\n",
       " 'Duration of Response',\n",
       " 'Safety and tolerability of a single and repeat dose intra-articular administration of UBX0101 evaluated by the incidence of serious and non-serious adverse events',\n",
       " 'Plasma UBX0101 drug concentrations following IA administration',\n",
       " 'Change from baseline to Week 12 of the Western Ontario and McMaster Universities Osteoarthritis Index pain subscale (WOMAC-A) score in patients receiving UBX0101 versus those receiving placebo',\n",
       " 'Change from baseline to Week 24 of the WOMAC-A score over time in patients receiving UBX0101 versus those receiving placebo',\n",
       " 'Change from baseline to Week 12 of the Western Ontario and McMaster Universities Osteoarthritis Index function subscale (WOMAC-C) score in patients receiving UBX0101 versus those receiving placebo',\n",
       " 'Change from baseline to Week 12 of the weekly mean of the average daily pain (ADP) intensity scores on the 11-point numeric rating scale (NRS) in patients receiving UBX0101 versus those receiving placebo',\n",
       " 'Epigenetic Analysis',\n",
       " 'Brain Imaging',\n",
       " 'Quality of life - European organization for research and treatment of cancer (EORTC) & Gastrointestinal quality of life index (GIQLI) preoperative',\n",
       " 'Quality of life - European organization for research and treatment of cancer (EORTC) & Gastrointestinal quality of life index (GIQLI) - postoperative 5 days',\n",
       " 'Quality of life - European organization for research and treatment of cancer (EORTC) & Gastrointestinal quality of life index (GIQLI) - postoperative 1 month',\n",
       " 'Quality of life - European organization for research and treatment of cancer (EORTC) & Gastrointestinal quality of life index (GIQLI) - postoperative 3 months',\n",
       " 'Numerical rating scale (NRS) for cosmetic result',\n",
       " 'Numerical rating scale (NRS) for cosmetic result',\n",
       " 'Visual analogue scale (VAS) for pain assessment - Postoperative 2hrs',\n",
       " 'Visual analogue scale (VAS) for pain assessment - Postoperative 1 day',\n",
       " 'Visual analogue scale (VAS) for pain assessment - Postoperative 2 days',\n",
       " 'Visual analogue scale (VAS) for pain assessment - Postoperative 3 days',\n",
       " 'Visual analogue scale (VAS) for pain assessment - Postoperative 5 days',\n",
       " 'Postoperative complications',\n",
       " 'Acute inflammatory Response - Preoperative',\n",
       " 'Acute inflammatory Response - Postoperative 2 hours',\n",
       " 'Acute inflammatory Response - Postoperative 2 days',\n",
       " 'Acute inflammatory Response - Postoperative 5 days',\n",
       " 'Occurrence of Anti-Retroviral Therapy (ART) (re)-initiation or ART modification, and reason (for ART modification)',\n",
       " 'CD4 count',\n",
       " 'Viral load (VL) and method of measurement',\n",
       " 'Occurrence of HIV disease progression',\n",
       " 'Occurrence of each separate defining condition for HIV-disease progression',\n",
       " 'Occurrence of specific clinical events and death',\n",
       " 'Occurrence of adverse events (AEs) or serious adverse events (SAEs) considered by the Investigator to be related to vaccination (performed in the preceding vaccination study)',\n",
       " 'Occurrence of potential immune-mediated diseases (pIMDs)',\n",
       " 'Occurrence of SAEs related to study participation',\n",
       " 'Time between dose 1 and ART (re)-initiation or ART modification',\n",
       " 'Time between dose 1 and CD4 count measurement',\n",
       " 'Time between dose 1 and VL measurement',\n",
       " 'Time between dose 1 and occurrence of HIV disease progression',\n",
       " 'Time between dose 1 and occurrence of each separate defining condition for HIV-disease progression',\n",
       " 'Antibody concentrations to vaccine antigens',\n",
       " 'Cell-mediated immunity responses',\n",
       " 'Additional exploratory immunogenicity endpoints (other T-cell immune markers or T-cell functional assays)',\n",
       " 'Myotube diameter of in vitro cultured myotubes',\n",
       " 'Expression and translation of markers of',\n",
       " 'Performance in simulated emergencies (medical performance and non-technical skills)',\n",
       " 'Stress in simulated emergencies (measured by salivary amylase and cortisol levels)',\n",
       " 'Progression free survival (PFS) (Phase II)',\n",
       " 'Overall survival (OS) (Phase III)',\n",
       " 'Incidence of grade 3 or higher adverse events',\n",
       " 'Overall survival (OS) (Phase II)',\n",
       " 'Progression free survival (PFS) (Phase III)',\n",
       " 'Objective response rate (ORR)',\n",
       " 'Percentage of subjects achieving a 90% or higher improvement from Baseline in Psoriasis Area and Severity Index (PASI) score at Week 12',\n",
       " \"Percentage of subjects with Investigator's Global Assessment (IGA) response at Week 12\",\n",
       " \"Percentage of subjects with Investigator's Global Assessment (IGA) response at Week 8\",\n",
       " 'Percentage of subjects achieving a 90% or higher improvement from Baseline in Psoriasis Area and Severity Index (PASI) score at Week 8',\n",
       " 'Percentage of subjects achieving a 75% or higher improvement in Psoriasis Area and Severity Index (PASI) score at Week 12',\n",
       " 'Percentage of subjects achieving a 100% improvement from Baseline in Psoriasis Area and Severity Index (PASI) score at Week 12',\n",
       " 'Surgical Site infection',\n",
       " 'Antibiotic Sensitivity',\n",
       " 'Clostridium Difficile Colitis',\n",
       " 'Antibiotic Resistance',\n",
       " 'Patient compliance',\n",
       " 'Cost',\n",
       " 'Usability of Course',\n",
       " 'Effectiveness of Course',\n",
       " 'Home dialysis survival',\n",
       " 'Patient survival, censored for technique failure',\n",
       " 'Home technique survival, censored for death',\n",
       " 'Wittener Panik Fragebogen (WPF)',\n",
       " 'WAF',\n",
       " 'Agoraphobic Cognition Questionnaire (ACQ)',\n",
       " 'Body Sensations Questionnaire (BSQ)',\n",
       " 'Mobility Inventory (MI)',\n",
       " 'Agoraphobic Self-Statements Questionnaire (ASQ)',\n",
       " 'Agoraphobic Cognitions Scale - extended version (ACS+)',\n",
       " 'Patient Health Questionnaire - D (PHQ-D) - Subscale Panic Syndrome',\n",
       " 'Brief Symptom Inventory (BSI)',\n",
       " 'Beck Depression Inventory (BDI)',\n",
       " 'Number of treatment emergent adverse events (TEAEs)',\n",
       " 'AUC(0-24) of BAY1101042',\n",
       " 'AUC(0-24)/D of BAY1101042',\n",
       " 'Cmax of BAY1101042',\n",
       " 'Cmax/D of BAY1101042',\n",
       " 'AUC,md of BAY1101042',\n",
       " 'AUC,md/D of BAY1101042',\n",
       " 'Cmax,md of BAY1101042',\n",
       " 'Cmax,md/D of BAY1101042',\n",
       " 'Assessment of the rate of Radiation-Induced CD8 T-Lymphocyte Apoptosis',\n",
       " 'Assessment of the rate and scores of late fibrosis related to irradiation by mammosite',\n",
       " 'Assessment of the rate of telangiectasia',\n",
       " 'Assessment of the rate of sequellar pain',\n",
       " 'Assessment of the rate of seroma collection',\n",
       " 'Assessment of the breast esthetic score',\n",
       " 'To determine if COH in IVF patients using Bravelle & Menopur with antagonists results in improved or equal IVF results compared to patients using agonist.',\n",
       " 'To determined if COH in IVF patients using Bravelle & Menopur with antagonists results in lower peak estradiol levels compared to agonist',\n",
       " 'To determine if COH patients using Bravelle & Menopur with antagonist antagonists results inn shorter period of stimulation compared with agonist.',\n",
       " 'Evaluate efficacy of REMEEX on urinary incontinence post radical prostatectomy',\n",
       " 'Evaluate efficacy of REMEEX on urinary incontinence post radical prostatectomy',\n",
       " 'Evaluate efficacy of REMEEX on urinary incontinence post radical prostatectomy',\n",
       " 'Evaluate efficacy of REMEEX on urinary incontinence post radical prostatectomy',\n",
       " 'Evaluate efficacy of REMEEX on urinary incontinence post radical prostatectomy',\n",
       " 'Evaluate efficacy of REMEEX on urinary incontinence post radical prostatectomy',\n",
       " 'Evaluate efficacy of REMEEX on urinary incontinence post radical prostatectomy',\n",
       " 'Normal clinical examination',\n",
       " 'Normal clinical examination',\n",
       " 'Normal clinical examination',\n",
       " 'Normal clinical examination',\n",
       " 'Normal clinical examination',\n",
       " 'Normal clinical examination',\n",
       " 'Normal clinical examination',\n",
       " 'urinary output',\n",
       " 'urinary output',\n",
       " 'urinary output',\n",
       " 'urinary output',\n",
       " 'urinary output',\n",
       " 'urinary output',\n",
       " 'urinary output',\n",
       " 'Volume of urine',\n",
       " 'Volume of urine',\n",
       " 'Volume of urine',\n",
       " 'Volume of urine',\n",
       " 'Volume of urine',\n",
       " 'Volume of urine',\n",
       " 'Volume of urine',\n",
       " 'Post-void residual urine volume',\n",
       " 'Post-void residual urine volume',\n",
       " 'Post-void residual urine volume',\n",
       " 'Post-void residual urine volume',\n",
       " 'Post-void residual urine volume',\n",
       " 'Post-void residual urine volume',\n",
       " 'Post-void residual urine volume',\n",
       " 'cystoscopy',\n",
       " 'cystoscopy',\n",
       " 'cystoscopy',\n",
       " 'cystoscopy',\n",
       " 'cystoscopy',\n",
       " 'cystoscopy',\n",
       " 'cystoscopy',\n",
       " 'readjustment of the REMEEX medical device',\n",
       " 'readjustment of the REMEEX medical device',\n",
       " 'readjustment of the REMEEX medical device',\n",
       " 'readjustment of the REMEEX medical device',\n",
       " 'readjustment of the REMEEX medical device',\n",
       " 'readjustment of the REMEEX medical device',\n",
       " 'readjustment of the REMEEX medical device',\n",
       " 'General improvement of symptoms',\n",
       " 'General improvement of symptoms',\n",
       " 'General improvement of symptoms',\n",
       " 'General improvement of symptoms',\n",
       " 'General improvement of symptoms',\n",
       " 'General improvement of symptoms',\n",
       " 'General improvement of symptoms',\n",
       " 'Improvement of urinary symptoms',\n",
       " 'Improvement of urinary symptoms',\n",
       " 'Improvement of urinary symptoms',\n",
       " 'Improvement of urinary symptoms',\n",
       " 'Improvement of urinary symptoms',\n",
       " 'Improvement of urinary symptoms',\n",
       " 'Improvement of urinary symptoms',\n",
       " 'Side effects or complications',\n",
       " 'Side effects or complications',\n",
       " 'Side effects or complications',\n",
       " 'Side effects or complications',\n",
       " 'Side effects or complications',\n",
       " 'Side effects or complications',\n",
       " 'Side effects or complications',\n",
       " 'Reliability and ease of use of the device',\n",
       " 'Reliability and ease of use of the device',\n",
       " 'Reliability and ease of use of the device',\n",
       " 'Reliability and ease of use of the device',\n",
       " 'Reliability and ease of use of the device',\n",
       " 'Reliability and ease of use of the device',\n",
       " 'Reliability and ease of use of the device',\n",
       " 'Patient incontinence-related quality of life',\n",
       " 'Patient incontinence-related quality of life',\n",
       " 'Patient incontinence-related quality of life',\n",
       " 'Patient incontinence-related quality of life',\n",
       " 'Patient incontinence-related quality of life',\n",
       " 'Patient incontinence-related quality of life',\n",
       " 'Patient incontinence-related quality of life',\n",
       " 'Patient sexual-related quality of life',\n",
       " 'Patient sexual-related quality of life',\n",
       " 'Patient sexual-related quality of life',\n",
       " 'Patient sexual-related quality of life',\n",
       " 'Patient sexual-related quality of life',\n",
       " 'Patient sexual-related quality of life',\n",
       " 'Patient sexual-related quality of life',\n",
       " 'Satisfaction of use by the surgeon.',\n",
       " 'Pharmacokinetic parameters AUC',\n",
       " 'Pharmacokinetic parameters Cmax',\n",
       " 'Pharmacokinetic parameters AUC',\n",
       " 'Pharmacokinetic parameters Cmax',\n",
       " 'Pharmacokinetic parameters AUC (to infinity)',\n",
       " 'Pharmacokinetic parameter RAUC (ratio of metabolite to parent)',\n",
       " 'Change in HbA1c from baseline to week 12',\n",
       " 'Percentage of subjects achieving HbA1c < 7% at week 12',\n",
       " 'Gut microbiome composition',\n",
       " 'Changes in postprandial glucagon-like peptide-1 (GLP-1) secretion between baseline and week 12',\n",
       " 'Adverse effects',\n",
       " 'Pain during anesthesia injection using the Wong-Baker faces scale',\n",
       " 'Pain during rubber dam placement using the Wong-Baker faces scale',\n",
       " 'Pain during tooth preparation using the Wong-Baker faces scale',\n",
       " 'Pain during pulp opening using the Wong-Baker faces scale',\n",
       " 'Pain during restoration placement using the Wong-Baker faces scale',\n",
       " 'Additional injections of local anesthetic at the first visit',\n",
       " 'Additional injections of local anesthetic at the second visit',\n",
       " 'All cause mortality (US FDA only)',\n",
       " 'All cause mortality (US FDA only)',\n",
       " 'Global Cure (EU only)',\n",
       " 'Global Cure (EU only)',\n",
       " 'Global Cure',\n",
       " 'Global Cure',\n",
       " 'Global Cure',\n",
       " 'Global Cure',\n",
       " 'All cause mortality (EU only)',\n",
       " 'All cause mortality (EU only)',\n",
       " 'Comparison of Global Response (as confirmed by the DRC)',\n",
       " 'Comparison of Global Response (as confirmed by the DRC)',\n",
       " 'Comparison of Mycological Response',\n",
       " 'Comparison of Mycological Response',\n",
       " 'Comparison of Clinical Cure',\n",
       " 'Comparison of Clinical Cure',\n",
       " 'Incidence of treatment emergent adverse events [Safety and Tolerability]',\n",
       " 'Evaluate Pharmacokinetics (Cmax)',\n",
       " 'Evaluate Pharmacokinetics (Time to Cmax [Tmax])',\n",
       " 'Evaluate Pharmacokinetics (AUC)',\n",
       " 'Comparison of Radiological Cure',\n",
       " 'Comparison of Radiological Cure',\n",
       " 'Step counts',\n",
       " 'Step counts',\n",
       " 'Step counts',\n",
       " 'SciBase Sensitivity and Specificity',\n",
       " 'Sensitivity and Specificity',\n",
       " 'Global Assessment of Function',\n",
       " 'PANSS',\n",
       " 'IMR Scale',\n",
       " 'Personal and Social Performance',\n",
       " 'Hamilton Rating Scale for Depression',\n",
       " 'Young Mania Rating Scale',\n",
       " 'Mental Health Recovery Measure',\n",
       " 'The Adult State Hope Scale',\n",
       " 'Testing the safety of anti-CD-20 in a small cohort of patients with debilitating fibrosing skin disorders.',\n",
       " 'Testing the efficacy of anti-CD-20 in a small cohort of patients with debilitating fibrosing skin disorders.',\n",
       " 'Myocardial fibrosis reduction:measure of Serum carboxy-terminal peptide of procollagen type 1.',\n",
       " 'Clinical improvement (New York Heart Association classification, signs and symptoms of heart failure)',\n",
       " 'Cardiovascular events',\n",
       " 'NT-proBNP (Brain Natriuretic Peptide)',\n",
       " 'Hospitalizations, home care due to cardiovascular causes related to heart failure',\n",
       " 'Safety and tolerability',\n",
       " 'Quality of Life (Minnesota Test)',\n",
       " 'Dynamic Posturography',\n",
       " 'Blinded expert judging of motor performance in Gymnastics',\n",
       " 'Percent Change from Baseline to 18 Months in Lumbar Spine BMD',\n",
       " 'Percent Change from Baseline in Lumbar Spine BMD',\n",
       " 'Percent Change from Baseline in Total Hip and Femoral Neck BMD',\n",
       " 'Percent Change from Baseline in Trabecular Volumetric BMD at the Lumbar Spine',\n",
       " 'Percent Change from Baseline in Cortical BMD at the Femoral Neck',\n",
       " 'Percent Change from Baseline in Trabecular BMD at the Femoral Neck',\n",
       " 'Percent Change from Baseline in Biochemical Marker -Serum Procollagen I C-Terminal Propeptide (PICP)',\n",
       " 'Percent Change from Baseline in Biochemical Marker -Serum Procollagen I N-Terminal Propeptide (PINP)',\n",
       " 'Percent Change from Baseline in Biochemical Marker -Bone-Specific Alkaline Phosphatase (BSAP)',\n",
       " 'Percent Change from Baseline in Biochemical Marker -Urinary N-Telopeptide (NTX)',\n",
       " 'Percentage of Participants with Nonvertebral Fractures',\n",
       " 'Percentage of Participants with Clinical Fractures',\n",
       " 'Change from Baseline on the Back Pain Questionnaire',\n",
       " 'Weight loss',\n",
       " 'Body composition',\n",
       " 'Dietary intake',\n",
       " 'Hunger and fullness',\n",
       " 'Lipid profile',\n",
       " 'Fasting blood glucose',\n",
       " 'C-reactive protein',\n",
       " 'Gastrointestinal symptoms and tolerance',\n",
       " 'Hepatic panel',\n",
       " 'Serum creatinine',\n",
       " 'Change in degree of arterial stiffness measured by pulse wave velocity',\n",
       " 'Changes in vascular calcification on CT scans of superficial femoral artery and aorta',\n",
       " 'Changes in bone mineral density',\n",
       " 'Changes in serum calcium and phosphate levels',\n",
       " 'Cardiovascular events including myocardial ischaemia, myocardial infarction, cardiac failure, stroke, PVD',\n",
       " 'Incidence of fractures',\n",
       " 'Symptoms and severity of side effects from alendronate',\n",
       " 'Episodes of hypocalcemia (serum corrected calcium <2.10mmol/L)',\n",
       " 'left atrial volume',\n",
       " 'diastolic function',\n",
       " 'systolic and diastolic blood pressure',\n",
       " 'Beck Depression Inventory Second Edition (BDI-II) score change between pre and post measurement',\n",
       " 'State-Trait Anxiety Inventory (STAI) scores change from pre to post training measurement',\n",
       " 'prevalence and incidence of resistance of cytomegalovirus',\n",
       " 'pharmacological and virological resistance',\n",
       " 'Housing placement',\n",
       " 'Patient retention in program',\n",
       " ...]"
      ]
     },
     "execution_count": 115,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "cls.tag_corpus['measure']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 130,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['Knee Injury an Osteoarhtritis Outcome Score (KOOS)',\n",
       " 'Bone microarchitecture of the distal radius',\n",
       " 'Bone microarchitecture of the distal radius',\n",
       " 'Bone microarchitecture of the distal radius',\n",
       " 'Bone microarchitecture of the distal radius',\n",
       " 'Bone microarchitecture of the distal radius',\n",
       " 'Bone microarchitecture of the distal radius',\n",
       " 'Change in Musculoskeletal Symptom Sub-scale on the Breast Cancer Prevention Trial Symptom Scale']"
      ]
     },
     "execution_count": 130,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "cls.tag_corpus['measure'][70:78]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 131,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['Knee Injury an Osteoarhtritis Outcome Score (KOOS)',\n",
       " 'Bone microarchitecture of the distal radius',\n",
       " 'Bone microarchitecture of the distal radius',\n",
       " 'Bone microarchitecture of the distal radius',\n",
       " 'Bone microarchitecture of the distal radius',\n",
       " 'Bone microarchitecture of the distal radius',\n",
       " 'Bone microarchitecture of the distal radius',\n",
       " 'Change in Musculoskeletal Symptom Sub-scale on the Breast Cancer Prevention Trial Symptom Scale']"
      ]
     },
     "execution_count": 131,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "\n",
    "cls.tag_corpus['measure'][70:78]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 82,
   "metadata": {},
   "outputs": [],
   "source": [
    "with open('./data/tag_100.txt', 'w') as f:\n",
    "    w = csv.writer(f,delimiter = '\\n')\n",
    "    w.writerow(tag_corpus)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 132,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['Patient reported symptoms, stiffness, pain, activities of daily living (ADL), function in sport and recreation and knee related quality of life',\n",
       " 'trabecular bone mineral density measurement (XCT)',\n",
       " 'bone volume fraction (%)',\n",
       " 'trabecular homogeneity (mm)',\n",
       " 'trabecular number (mm-1)',\n",
       " 'trabecular thickness (mm)',\n",
       " 'trabecular separation (mm)',\n",
       " 'The MS subscale is a self-reported measure on a scale of 0 to 4, with lower score indicating less arthralgia/myalgia']"
      ]
     },
     "execution_count": 132,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "cls.tag_corpus['description'][70:78]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 129,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['NCT02788461; Non-Small Cell Lung Cancer',\n",
       " 'NCT02788461; Non-Small Cell Lung Cancer',\n",
       " 'NCT02788461; Non-Small Cell Lung Cancer',\n",
       " \"NCT01569503; Crohn's Disease\",\n",
       " \"NCT01569503; Crohn's Disease\",\n",
       " \"NCT01569503; Crohn's Disease\",\n",
       " \"NCT01569503; Crohn's Disease\"]"
      ]
     },
     "execution_count": 129,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "cls.tag_corpus['NCT'][33:40]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.7.5"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
